updated 5/2019

CURRICULUM VITAE

Raymond Charles Bergan DeArmond Chair of Cancer Research

Chief, Division of Hematology & Medical Oncology Associate Director, Knight Cancer Institute

Professor of Medicine Oregon Health & Science University

Work Address: Raymond C. Bergan, M.D. Division of Hematology/Oncology 3181 SW Sam Jackson Blvd L586 Portland, OR 97239-3098 tele: 503-494-5325 fax: 503-494-4285 e-mail: bergan@ohsu.edu Home Address: 1227 SW Gaines St

Portland, OR 97239 Personal Data: Birth Date: 12/28/58 Citizenship: United States Marital Status: Married Children: Three

Education 6/79 - 6/83 Bachelors of Science in Biochemistry State University of New York at Buffalo Buffalo, New York Honors in Biochemistry 8/83 -6/87 Doctor of Medicine

State University of New York Health Science Center at Syracuse Syracuse, New York 11-2015 Leadership Development Course

Harvard T.H. Chan School of Public Health

2

Boston, MA Postdoctoral Training 7/87 - 6/90 Internship and Residency in Internal Medicine State University of New York Health Science Center at Syracuse Syracuse, New York 7/90 - 6/93 Fellowship in Medical Oncology Medicine Branch National Cancer Institute National Institutes of Health Bethesda, Maryland 8/93 – 7/98 Research Fellowship in Drug Discovery

Clinical Pharmacology Branch and Medicine Branch National Cancer Institute National Institutes of Health Bethesda, Maryland Employment History Summer 1981 - Summer 1982 Research Assistant J. H. Wang Department of Biochemistry State University of New York at Buffalo Buffalo, New York 8/94-8/95 Staff Physician Shady Grove Adventist Hospital Gaithersburg, Maryland 9/98-9/05 Assistant Professor 9/05 Associate Professor (tenure 2007) 5/10-1/2015 Professor Department of Medicine (primary appointment)

Division of Hematology/Oncology Northwestern University Chicago, IL 9/05 Associate Professor

3

5/10-1/2015 Professor Department of Preventive Medicine

Northwestern University Chicago, IL 3/1999-1/2015 Staff Physician (WOC then part time employee) Division of Hematology/Oncology

Jesse Brown Veterans Administration Hospital Chicago, IL

1/2015 Chief, Division of Hematology & Medical Oncology

Associate Director Knight Cancer Institute DeArmond Chair of Cancer Research Professor of Medicine Oregon Health & Science University Portland, OR

1/2015 Professor of Medicine

Department of Cell, Developmental & Cancer Biology Oregon Health & Science University Portland, OR

3/2015 Staff Physician (WOC then part time employee) Division of Hematology/Oncology

Portland Veterans Administration Hospital Portland, OR

Research narrative: Our basic laboratory and our clinical research programs have both been continuously funded since 1999 by national level peer reviewed funding. Together they integrate cancer biology with drug discovery and molecular pharmacology, and do so across the basic and clinical research spectrum. The basic laboratory program. We seek to understand how human cancer cells regulate motility, transformation to the metastatic phenotype, and how that process can be therapeutically modulated. Our leadership in this area is demonstrated our group being the first to successfully therapeutically target pro-metastatic pathways in humans, thus achieving a long sought goal of experimental therapeutics (JNCI 2009), by our DOD Prostate Cancer Research Program, Laboratory-Clinical Transition Award being funded at the 1%ile level, by our Veterans Merit Award funded at the 1.5%ile level and most recently by WIRED magazine citing our work as a “monumental discovery”. We have discovered and patented a novel acting potent anti-motility agent (Nature Communications, 2018; Altmetric 98%ile for all journals), and went on to found Third Coast Therapeutics (3CRx) with the primary goal of moving that agent into successful clinical trials.

4

The clinical program. Under my guidance, we developed one of only five NIH/NCI funded early phase cancer chemoprevention clinical trials programs, successfully directed it from inception through two funding cycles from 2003 – 2015, expanded it to nineteen sites, inclusive of two in China.. Upon leaving Northwestern University, I handed off directorship of this program. The Program was structured to impact the field, and major accomplishments include: -demonstrated that direct delivery of chemopreventive agents to at risk organs, e.g. breast, maintains chemopreventive efficacy while avoiding systemic toxicity (Clinical Cancer Research 2014). By removing systemic toxicity, a major limiting barrier for chemopreventive agents has been overcome. Based upon this, we launched several additional trials deploying this strategy targeting lung (one trial), colon (two), and breast (one). Our review of these advances (Cancer Prevention Research 2016) led NCI to develop a RFP (NIH/NCI 374) for SBIR proposals to develop novel local delivery vehicles. -demonstrating for the first time that it is possible to measure therapeutic reversion of a basic measure of carcinogenesis, i.e. chromatin remodeling, in at risk histologically normal tissue in real time at the single patient level (Gut 2017). We did so using spectral imaging, a novel technology that can be applied to essentially all epithelial surfaces. This achievement allows real time monitoring of therapeutic efficacy of chemopreventive agents, and thereby overcomes a major barrier to the field, and is poised to transform the field. With funding from the Hebei Science Foundation, we are now testing the ability of this technology to detect esophageal cancer in high risk cohorts in China. -we successfully implemented the first NCI sponsored early phase chemoprevention trial in China (in Xi’an). This provides access to highly informative at risk cohorts. I remain Study Chair of this phase I trial in subjects at risk for colon cancer.

In separate work, I serve as Co-PI of a $15M project, funded by private donors, and as PI of the associated clinical protocol, entitled the “Serial Measurement of Molecular and Architectural Response to Treatment (SMMART) Trial”. This initiative seeks to comprehensively characterize individual’s tumors through a multi-omic analysis, leading to real time delivery of multiple agents simultaneously to a single patient with advanced cancer so as to target multiple driver pathways. Major administrative responsibilities narrative: -PI/Director NCI funded Early Phase Chemoprevention Program. Founded, and then grew to nineteen institutions; served as PI of all trials; funded 42 different people during first funding cycle, 24 of them faculty. Total funded initiative under my directorship = $23M. -Leader Prevention Program under Northwestern University CCSG: improved program ranking through two CCSG funding cycles -Co-founder, Co-Director, Northwestern Center for Molecular Innovation and Drug Discovery; cooperatively facilitated expansion of facilities, faculty, funding and scientific advances. -Interim Director, Northwestern Prostate SPORE Program. Charged by the Cancer Center Director to affect changes in the program so as to achieve successful re-competition. This was achieved successfully. -Chief, Division of Hematology/Oncology, Associate Director, Knight Cancer Institute. The following were accomplished during my tenure at OHSU: recruited 37 faculty into the division, expanding it to 103 faculty and reorganized into seven sections; increased portfolio and amount

5

of national level peer reviewed funding; increased new patient numbers by 23% and expanded market share; increased accrual to therapeutic clinical trials by 50%; expanded the fellowship program from 9 to 12 fellows; assumed Co-Leadership of the newly formed Translational Oncology Program for the CCSG application; achieved NCI designated Comprehensive Cancer Status for the first time; designed two buildings: one basic science (opened 9/2018), one clinical (opens 4/2019). -Assumed Chair ECOG-ACRIN Prevention Committee, Fall 2015. Outside Interests I enjoy learning Mandarin Chinese, reading and exercising, Professional Licensure Medical License in State of New York (prior; 175089-1) Medical License in State of Maryland (prior; 041257) Medical License in State of Illinois (prior; 336-059410) Medical License in State of Oregon: MD170752 Federal DEA (Oregon): FB5045528 ESA APPRISE Oncology Program enrollment identification Enrollment ID: 436861507

Professional Appointments 7/91-6/93 Staff Fellow, Tumor Cell Biology Section, Clinical Pharmacology Branch, National Cancer Institute, Bethesda, Maryland 1992 Chief Fellow, Medical Oncology, National Naval Medical Center, National Cancer Institute, Bethesda, Maryland 7/93-8/95 Clinical Investigator, Tumor Cell Biology Section, Clinical Pharmacology Branch, National Cancer Institute, Bethesda, Maryland 7/93-7/98 Staff Attending, Special Studies Clinic, Clinical Pharmacology Branch, National Cancer Institute, Bethesda, Maryland 4/95-11/96 Staff Attending, Multi-Drug Resistance Clinic, Medicine Branch, National

Cancer Institute, Bethesda, Maryland 11/96-7/98 Principal Investigator, Tumor Cell Biology Section, Clinical Pharmacology Branch, National Cancer Institute, Bethesda, Maryland 2/97 Member, Therapeutic Oligonucleotides Interest Group Steering Committee 9/98-1/2015 Member, Robert H. Lurie Comprehensive Cancer Center of

Northwestern University, Chicago, IL 5/98--1/2015 Director, Experimental Therapeutics, Robert H. Lurie Comprehensive

Cancer Center of Northwestern University, Chicago, IL 12/98-1/00 Co-Leader, Prostate Cancer Program, Robert H. Lurie Cancer

Center 9/99- Faculty Member, Northwestern University Drug Discovery Program

6

1/00-8/2005 Co-Leader, Cancer Prevention Program, Robert H. Lurie Cancer Center

8/2005-1/2015 Leader, Cancer Prevention Program, Robert H. Lurie Cancer Center

6/01-7/03 Co-Director, Northwestern University Prostate SPORE Program 8/01-7/03 Director, GU Oncology Clinic, Veterans Administration Lakeside Hospital 7/03-6/04 Interim Director, Northwestern Prostate SPORE Program 6/03-1/2015 Faculty Member, Northwestern University Integrated Graduate Program 4/04-1/2015 Faculty Member, Northwestern University Cancer Epidemiology and

Prevention Program 4/06-1/2015 Faculty Member, Northwestern Program in Computational Biology &

Bioinformatics 1/07-1/2015 Associate Professor, Professor, Department of Preventive Medicine,

Northwestern University 6/2008-1/2015 Faculty Member, Northwestern Medical Scientist Training Program 1/2009-1/2015 Co-Founder and Director, Northwestern University Center for Molecular

Innovation and Drug Discovery 6/2010-1/2015 Faculty Member, Northwestern Masters in Biotechnology Program 12/2010-2012 Leader, Experimental Therapeutics Interest Group, Translational Research

Program, Robert H. Lurie Cancer Center 1/2010 Co-Chair, American Association of Cancer Research 2010 Frontiers in

Cancer Prevention Annual Meeting. 6/2010 Chair, Prostate Cancer Educational Session, American Association of

Cancer Research 2010 Frontiers in Cancer Prevention Annual Meeting. 6/2012-1/2015 Visiting Professor, Fourth Military Medical University, Xi’an,

China 5/2013 Chair, Tumor Microenvironment Session, 6th Annual World Cancer Congress-2013, Xi’an, China 11/2013- Visiting Professor, Fudan University, Shanghai, China 1/2015- Associate Director, Knight Cancer Center, Knight Cancer Institute 1/2015- Chief, Division of Hematology/Oncology, Knight Cancer Institute, Oregon

Health & Sciences University 1/2015- Member, Faculty Practice Plan Board, Oregon Health & Sciences

University 1/2015- Member, Clinical Department Chairs Group, Oregon Health & Sciences

University 1/2015- Member, Clinical Executive Group, Knight Cancer Institute, Oregon

Health & Sciences University 2/2015- Co-Leader, Translational Oncology Program, Knight Cancer Institute,

Oregon Health & Sciences University 7/2015- International Collaborator, International Collaboration Grant (PI:

Guangmei Yan; Sun-yat Sen University; funded by China National Science Foundation)

9/2015- Chair, Prevention Committee, Eastern Cooperative Oncology Group- American College of Radiology Imaging Network (ECOG-ACRIN)

7

11/2018- Faculty, Program in Molecular and Biosciences, OHSU, graduate program Clinical and Hospital Service Responsibilities Current • Hospital service: Oregon Health & Science University Hospital and Portland Veterans

Administration Hospital • Outpatient Clinic: Oregon Health & Science University Hospital and Portland Veterans

Administration Hospital outpatient clinics Prior (8/98-1/2015) • Hospital service: Jesse Brown Veterans Administration Hospital, and Northwestern

Memorial Hospital • Clinic: Jesse Brown Veterans Administration and Northwestern Medical Faculty Foundation

clinics Committees 1/96-7/98 Member, Institutional Review Board, Clinical Center, National Cancer Institute, Bethesda, Maryland 12/96 Chairperson, First NIH Symposium on Therapeutic Oligonucleotides, Bethesda, Maryland 12/97 Invited Round Table Discussant; Second NIH Symposia on Therapeutic Oligonucleotides: Targeting Transcription Factors and Signaling Pathways 3/98 Invited Panel Discussant, Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics 10/98-1/2015 Ad Hoc Member, Robert H. Lurie Comprehensive Cancer Center Clinical

Protocol Scientific Review and Monitoring Committee 10/98 Northwestern University State Representative to Illinois Comprehensive

Cancer Control Initiative 10/98 Northwestern Site Coordinator, Chicago Experimental Therapeutics

Group 12/98-1/2015 Member, Cancer Center Leadership Committee 7/99 Member NMFF Strategic Planning Implementation Task Force for

Urogenital Cancer Program 8/99 Panel Leader for NCI Workshop on “Prevention of Prostate

Cancer” 11/99 Member, Cancer Prevention Working Group, for the Cancer Center

Research Foundation of America 1999-1/2015 Member, Internal Resident Interview Panel, Feinberg School of Medicine, Northwestern University 1/00-1/2015 Co-Director, Cancer Center Laser Capture Microdissection Core Facility

8

4/01-2005 Member, LabSac Eastern Cooperative Oncology Group (ECOG) sub-committee

6/01-1/2015 Member, Prostate SPORE Executive Committee 8/01-9/2013 Chair, Cancer Center Pathology Core Facility Internal Advisory Committee 10/02-9/2006 Member, Northwestern General Clinical Research Center (GCRC) Scientific Advisory Committee (SAC) 11/02-2008 Member, Prostate SPORE Pathology Core Tissue Utilization Committee 2002 Member, Search Committee for Director of Cancer Prevention and Control, Robert H. Lurie Comprehensive Cancer Center, and Department

of Preventive Medicine, Feinberg School of Medicine, Northwestern University

7/03-present Member, Eastern Cooperative Oncology Group – American College of Radiology Imaging Network (ECOG-ACRIN) Prevention Committee 8/03-2006 Member, Northwestern Memorial Hospital Research Committee 8/04-1/2015 Founding Member, Steering Committee for University Center for Drug Discovery and Chemical Biology 10/05-6/07 Member, Jesse Brown Veterans Administration Medical Center Research and Development Committee 1/08-2009 Member, Veterans Administration National Oncology Advisory Committee 2007-1/2015 Member, Interviewer Panel for Medical Scientist Training Program (MSTP) Candidates 2008 Member, Grant Review Committee, Northwestern American Cancer Society Grant (local ACS grant) 2008 Member, Search Committee for Cancer Epidemiologist, Department of

Preventive Medicine 2009-1/2015 Member (sole), Selection Committee for Cancer Center’s Cancer

Prevention Travel Award 2009-1/2015 Member, Grant Review Committee, Northwestern University Clinical and

Translational Sciences Institute (NUCATS), now renamed the Dixon Translational Research Grants program

2009-2011 Member, University-Wide Tissue Banking Assessment and Recommendation Committee, Feinberg School of Medicine, Office of Research and NUCATS.

8/09 Member, Search Committee for Prostate SPORE Director 11/09 Ad Hoc Chair, Eastern Cooperative Oncology Group (ECOG) Prevention Committee 6/2010-2013 Member, Internal Advisory Committee for the Mouse

Phenotyping/histology Core facility 7/2010-1/2015 Core Leader for the Minority Biospecimen/Biobanking Core 9/2010 Panel Discussion Member for the NIH Director’s Scientific Management

Review Board (SMRB), Evaluating the role for NIH in the evolving landscape of translational medicine and therapeutics development.

9

10/2010 Ad Hoc Chair, Promotion and Tenure Committee, Northwestern University

12/2010-1/2015 Member, Northwestern University/Veterans Administration Combined Institutional Review Board (IRB).

3/2012-2014 The University of Arizona Cancer Center, External Advisory Board 3/2012-1/2015 Chair, Internal Advisory Committee, Mary Beth Donnelley Clinical

Pharmacology Core Facility 4/2012-1/2015 The University of Illinois at Chicago, External Advisory Committee, T32

training grant on Hormones in Cancer Research 10/2012 Ad Hoc Member, Promotion and Tenure Committee, Northwestern

University 11/2012 Member, Department of Pharmacology Chair Search Committee,

Northwestern University 2/2014 Member, Department of Urology Chair Search Committee, Northwestern

University 4-2014 Chair, Northwestern University Developmental Therapeutics Core Internal Advisory Committee 6/2014 External Referee, Promotion and Tenure Committee, Department of

Pharmaceutical and Biomedical Sciences at the University of Georgia, College of Pharmacy

3/2015- Member, Executive Design Committee, Knight Cancer Research Building 3/2015- Member, Executive Design Committee for SRG Architects, Center for

Health & Healing South 6/2015 Interim Chair, Prevention Committee, Eastern Cooperative Oncology

Group-American College of Radiology Imaging Network (ECOG-ACRIN) cooperative clinical trials group. *nominated for Chair

8/2015 Member, Cancer Drug Pricing Advisory Session for Congressman Earl Blumenauer

9/2015- Chair, Prevention Committee, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) cooperative clinical trials group.

12/2015 Member, Search Committee for Director, Linus Pauling Institute, Oregon State University

11/2016 Chair AACR 2016 Annual Meeting Program Committee for Clinical Prevention

11/2016 Member AACR 2016 Annual Meeting Scientific Program Committee for Preclinical Prevention

12/2016- Member University of Arizona, Native American Cancer Prevention (NACP) U54 Program Steering Committee (PSC).

2/2017- Co-Chair/member, Chicago Cancer Health Equity Collaborative U54 Program Steering Committee (PSC).

7/2017- Member, The Center for Radiochemistry Research, Internal Advisory Committee

7/2017- Member, National Cancer Institute (NCI) Prevention Steering Committee (PSC)

10

12/2017- Member, National Cancer Institute (NCI) PREVENT Program External Steering Panel

9/2017 Member, OHSU Department of Pathology Internal Review Committee 6/2018- Member, National Cancer Institute (NCI) PREVENT Program External

Advisory Committee Honors and Awards 6/83 Honors in Biochemistry, University of Buffalo 8/96 Equal Employment Opportunity Recognition Award, US National

Institutes of Health 10/96 “Outstanding Abstract”, American Society for Bone Marrow Transplantation, Abstract (1997) 12/97 Unit Commendation Medal, Public Health Service 10/00 Preceptor for Northwestern University Drug Discovery Scholar

Program (Awardee: Steven Hayes) 12/00 Preceptor for Robert H. Lurie Cancer Center Gramm Travel

Fellowship Award (Awardee: Yueqin Liu) 12/02 Principal Investigator of Department of Defense, Prostate

Cancer Research Program, Idea Development Grant, ranked at 2%ile, PC020418, Molecular Correlates of Soy in Humans

6/03 Best Teacher, Department of Medicine, Northwestern University 4/04 Preceptor for Robert H. Lurie Cancer Center Gramm Travel

Fellowship Award (Awardee: Xiaoke Huang) 3/06 Preceptor for Katten Muchin Rosenman Travel Scholarship

Program (Awardee: Minalini Lakshman) 3/2008 Cancer Research paper selected for press release by the American

Association for Cancer Research (AACR), Dietary genistein inhibits metastasis of human prostate cancer, Cancer Research, 68: 2024, 2008

3/2008 NIH RAPID Proposal Ranked #1: Development of drugs that prevent progression of prostate cancer to a metastatic phenotype

Mentor for Rebecca Farmer’s NIH F31 pre-doctorial training grant, review panel score = 110, title: Discovery of molecular inhibitors of prostate cancer metastasis.

7/2008 Mentor for Michael Lin (Northwestern medical student), recipient of a Dean’s Medical Student Scientist Research Program (MSSRP) grant.

1/2010 Appointed Co-Chair, American Association of Cancer Research 2010 Frontiers in Cancer Prevention Annual Meeting.

5/2010 Mentor for Mark Sparrow (Northwestern medical student), recipient of a Dean’s Medical Student Scientist Research Program (MSSRP) grant.

6/2010 Appointed Chair, Prostate Cancer Educational Session, American Association of Cancer Research 2010 Frontiers in Cancer

11

Prevention Annual Meeting. 9/2010 Panel Discussion Member for the NIH Scientific Management

Review Board (SMRB), Evaluating the role for NIH in the evolving landscape of translational medicine and therapeutics development.

5/2012 Keynote Speaker. Annual Conference American Council for Medicinally Active Plants

6/2012 Inducted as Visiting Professor, Fourth Military Medical University, Xi’an, China

5/2013 Chair, Tumor Microenvironment Session, 6th Annual World Cancer Congress-2013, Xi’an, China

5/2013 Sankar Krishna (graduate student), Received Protein Science Young Investigator Travel Grant / Protein Society Finn World Travel Award

7/13 Third Coast Therapeutics, Inc., (Founder, owner, and Board of Directors), selected for admission into the Chicago Innovation Mentors Program

8/2013 Third Coast Therapeutics, Inc., (Founder, owner, and Board of Directors), selected for admission into the Illinois Biotechnology (iBIO) Institute’s PROPEL Program

11/2013 Inducted as a Visiting Professor, Fudan University, Shanghai, China

2/2014 Sankar Krishna (graduate student), Received Chemical Biology and Drug Discovery Cluster Travel Stipend, to AACR 2014 meeting.

11/2014 Designated one of “The Fifty” for Northwestern – identifies top 50 grantees across the whole university

1/2015 Installed as the DeArmond Chair of Cancer Research endowed chair

3/2015 Principal Investigator of Department of Defense, Prostate Cancer Research Program, Laboratory-Clinical Transition Award, ranked at 1%ile; PC141395, Inhibiting prostate cancer cell motility. 6/2015 Principal Investigator of Veterans Administration Merit Award ranked at 1.5%ile; IBX002842A, Therapeutically targeting cancer cell motility 6/2015 Interim Chair, Prevention Committee, Eastern Cooperative

Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) cooperative clinical trials group.

9/2015 Chair, Prevention Committee, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) cooperative clinical trials group.

10/2015 Group Leader, Harvard School of Public Health, Leadership Development Program

11/2015 Member, NCI Cancer Prevention Think Tank Meeting 7/2017- Member, National Cancer Institute (NCI) Prevention Steering Committee (PSC)

12

12/2017- Member, National Cancer Institute (NCI) PREVENT Program External Steering Panel

6/2018-5/2020 Expert Consultant for the Hebei Administration of Foreign Experts Affairs 9/2018 Opening Ceremony Speaker, Hebei International Forum on Theory and Practice of Cancer Prevention and Control, Shijiazhaung, China 1/2019 In WIRED magazine article, “Why Your Doctor Should Also Be a Scientist”, our work was cited as monumental. Professional Affiliations 1987 Member, Associate American College of Physicians 1992-1993 Zacchaeus Medical Clinic Advisory Committee 1993-2000 Member, American Association for the Advancement of Science 1994- Member, American Association for Cancer Research (12120) 1/1996-1998 Charter Member, National Cancer Institute Antisense Interest Group 8/99-2015 Member, Illinois Medical Society 10/1998- Member, Eastern Cooperative Oncology Group-American College of

Radiology Imaging Network (ECOG-ACRIN Cancer Research Group) 5/1999- Member, American Society of Clinical Oncology 3/2015- Member, Oregon Medical Society 9/2015- Member, SWOG (membership ID: 26694) Editorial Activities Member 8/05-12/09 Editorial Board, Cancer Epidemiology,

Biomarkers and Prevention Member 10/07 Scientific Review Committee, 2007 AACR

International Conference on Frontiers in Cancer Prevention Research.

Member 10/09 Scientific Review Committee, 2009 AACR International Conference on Frontiers in Cancer Prevention Research.

Member 12/2009- Editorial Board, Clinical Cancer Research Member 2/2015- Editorial Board, Cancer Prevention Research Ad hoc External Advisory Board 1993 Physician Desk Query,

Clinical Trials Database Reviewer 1995- Cancer Research Reviewer 8/96- Journal of the National Cancer Institute Reviewer 8/96 American Board of Internal Medicine

13

Reviewer 12/96- Cancer Reviewer 5/97 Journal of Biotechnology Reviewer 9/97 Oncology Research Reviewer 12/97- European Journal of Cancer Reviewer 9//98- Journal of Clinical Oncology Reviewer 11/98- International Journal of Cancer Reviewer 9/99- Urology Reviewer 3/02- Oncogene Reviewer 6/02- Clinical Cancer Research Reviewer 4/03 Hepatology Reviewer 6/05 J. Molecular Diagnostics Reviewer 3/06 Chemico-Biological Interactions Reviewer 3/06- Cancer Chemotherapy and Pharmacology Reviewer 3/10-onward American Journal of Pathology Reviewer 7/10 J. Experimental & Clinical Cancer Research Reviewer 8/10 J. Signal Transduction Reviewer 10/10- BMC Cancer Reviewer 11/10- Cancer Discovery Reviewer 9/2011- Molecular Cancer Research Reviewer 4-2013 Molecular Research in Urology Reviewer 8-2013- Oncotarget Reviewer 10-2015- Asian Journal of Andrology Reviewer 2-2017- JAMA Oncology Reviewer 3-2017- Proceedings National Academy of Sciences Grant Review Activities Ad hoc Member 1996 Source Evaluation Group, phase I Cancer Prevention Trials, Division for Cancer

Prevention and Control, National Cancer Institute

Ad hoc Member 1998 Source Evaluation Group, phase II Cancer Prevention Trials, Division for Cancer

Prevention and Control, National Cancer Institute

Reviewer 1999 Association for International Cancer Research, United Kingdom

Member 4/00-7/03 Illinois American Cancer Society Research Advisory Committee

Member 10/01-1/15 Northwestern Memorial Foundation Research Committee

Member 6/02-6/04 Member, NCI/NCCAM Ad Hoc Grant

14

Review Panel for Developmental Projects in Cancer Complementary and Alternative Medicine

Member 11/02 Member, NCI Grant Review Panel for Cooperative grants for nutritional modulation of genetic pathways leading to cancer

Ad hoc Member 5/04 NCI Site Visit Team for Ohio State University Comprehensive Cancer Center P30 competitive grant renewal

Invited 4/04 Oncology merit review committee (ONCB); refused secondary to being invited as a full member on NIH study section

Ad hoc Member 4/04-7/05 NIH Study section, Cancer Etiology Member 7/05-6/09 NIH Study section, Cancer Etiology Member 1/2010- NIH College of Center for Scientific Review

(CSR) Reviewers Ad hoc Member 12/2010 NCI Site Visit Team for Oregon

State University Comprehensive Cancer Center P30 competitive grant renewal

Ad hoc Member 2/2011 NCI Site Visit Team for University of California at Davis Cancer Center P30 competitive grant renewal

Member 5/2011 NIH/NCI Special Emphasis Panel/Scientific Review Group ZRG1 OTC-B (02), Chemodietary Prevention

Reviewer 5/2011 The Erwin Schroedinger Program, Erwin Schroedinger Fellowship applications for the Austrian Science Fund (FWF)

Ad hoc Member 10/2011 NCI Site Visit Team for University of Michigan Cancer Center P30 competitive grant renewal

Member 3/2012 NIH, Special Emphasis Panel/Scientific Review Group, NIH ZCA1 SRLB-9 (M1) R Provocative Questions (R01)

Member 3/2012 NIH, Special Emphasis Panel/Scientific Review Group, NIH ZCA1 SRLB-D (M1) R Provocative Questions R21

Ad hoc Member 2/2012 NIH/NCI study section, Chemodietary Prevention Member 6/2012-1/2015 Dixon Translational Research Council,

Northwestern Memorial Hospital Ad hoc Member 10/2012 NCI Site Visit Team for Case Western University

Cancer Center P30 competitive grant renewal Member 11/2012 NIH, Special Emphasis Panel/Scientific

15

Review Group, ZCA1 SRLB-1 (J1) R, NCI Cancer Biology, omnibus R21/R03 applications

Member 2/2013 NIH, Special Emphasis Panel/Scientific Review Group, Cancer Therapeutics

Member 3/2013 NIH, Special Emphasis Panel/Scientific Review Group, ZCA1 SRLB-1 (M2) B, NCI Cancer Biology, omnibus R21/R03 applications

Member 6/2013 NIH, Special Emphasis Panel/Scientific Review Group, Cancer Therapeutics, ZCA1 RPRB-M

Member 4/2014 NIH, Special Emphasis Panel/Scientific Review Group, NCI review of K01 and K22 Career Development applications, ZCA1 RTRB-A (M1) R

Member 6/2014 NIH, NCI Omnibus R21/R03 Special Emphasis Panel 4, Carcinogenesis and Biomarkers

Member 1/2016 NIH, NCI 2016 Cancer Clinical Investigator Team Leadership Awards (CCITLAs)

Discussion Leader 6/2017 NIH, NCI Special Emphasis Panel/Scientific Review Group 2017/10 ZCA1 RPRB-6 (O1), P01 review panel I

Member 7/2017- National Cancer Institute (NCI) Prevention Steering Committee (PSC): review proposals for cancer prevention trials to be implemented through the NCI NCORP cooperative group networks. Member 10/2017 NIH, NCI Special Emphasis Panel/Scientific

Review Group 2018/01 ZCA1 RPRB-F (J1) P, P01 review panel I

Member 12/2017- NIH, NCI PREVENT Program External Steering Panel.

Member 2/2018 NIH, NCI Technical Evaluation Panel, SBIR proposals; local delivery of chemopreventive agents

Discussion Leader 1/2018 NIH, NCI Genitourinary SPORE Review Meeting Member 6/2018 NCI Clinical R01 study section; ZCA1 RPRB-F

(O2) S. Member 5/2019 NCI Special Emphasis Panel/Scientific Review

Group 2019/08 ZCA1 SRB-2 (A1) R meeting; Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (PAR-18-767, U54s

Member 7/2019 NCI Special Emphasis Panel, Chemo/Dietary Study Section

Teaching/Education Responsibilities

16

7/93-6/98 Direct Supervisory Responsibility for Medical Staff Fellows, Clinical Oncology Program, Division of Clinical Sciences, National Cancer Institute, Bethesda, Maryland 6/94-6/98 Special Studies Clinical Teaching Conference, Clinical Oncology Program, Division of Clinical Sciences, National Cancer Institute, Bethesda, Maryland 4/95-6/98 Journal Review: Medical Staff Fellows, Clinical Oncology Program, Division of Clinical Sciences, National Cancer Institute, Bethesda, Maryland 6/96-6/98 Responsible for training college graduates interested in careers in

biomedicine in basic laboratory and research techniques, National Cancer Institute

12/96-6/98 Responsible for training Post-Doctoral Fellows for careers as independent researchers, National Cancer Institute

9/98-1/15 Responsible for the Direct Supervision and Teaching of Medical Oncology Fellows, Residents, Interns and Medical Students, related to the clinical activities of the Division of Hematology/Oncology, Northwestern University, Chicago, IL

9/98-2002 Weekly Genitourinary tumor board. 3/99-2011 Teach Module in graduate course, Advanced Topics in Drug

Discovery, Department of Molecular Pharmacology (Coordinated by Martin Waterson)

6/99-6/00 Organizer for monthly Experimental Therapeutics Seminar Series. 6/00-present Laboratory Mentor for CURE summer students 6/00-1/15 Laboratory Mentor for Drug Discovery Program summer students 8/99-12/02 Organizer for Annual Review of Research Topics: An eight-week

long weekly seminar series providing an overview of ongoing research within the Division for Fellows in Hematology/Oncology.

4/01-11/03 Teach module in Cancer Therapy for Tumor Cell Biology Course (Coordinated by Cara Gartardi).

2004 Developed the Genitourinary Core Curriculum for Fellows, for review by the Accreditation Committee

6/03-1/2018 Faculty, Integrated Graduate Program: preceptor for lab rotation students, qualification exams, thesis committee advisor

3/04-2009 Core instructor for NIH funded Cancer Epidemiology and Prevention Graduate Training Program. Designed and taught (will teach annually) PH 529, Cancer Chemoprevention; a 0.5 credit graduate level course.

2009-2015 Prostate Cancer: Tumor Cell Biology Course 2010-2015 Translational Research: Masters of Science in Clinical

Investigation Core Course 2011-2015 Molecular and Nanotherapy: Translational Medicine Course 2013-2015 Prostate Cancer Biology: Intermediate Epidemiology Class 2014-2015 Preventive Oncology: Heme/Onc module for second year medical

students

17

1/2015- Responsible for the Direct Supervision and Teaching of Medical Oncology Fellows, Residents, Interns and Medical Students, related to the clinical activities of the Division of Hematology/Oncology, Knight Cancer Institute

1/2015- Knight Cancer Institute, Fellowship Program in Hematology/Oncology; responsible to ensuring that Program meets ACGME requirements, for funding the Program and for candidate selection; also responsible for re-design of Program, inclusive of its didactic educational courses.

8/2017- Palliative Care Fellowship training program; the Division took over Directorship responsibility for this program, and is responsible for all aspects of it.

Laboratory Mentor and Training Responsibilities

Involvement with Specific Training programs: Prior: Role: Preceptor; Grant #: T32CA09560, Molecular Carcinogenesis Training Grant (PI: Green) Role: Core Faculty; Grant #: CA100600, Postdoctoral Training Program in Cancer Epidemiology and Prevention (PI: Gapstur) Role: Preceptor, T32 AG00260, Drug Discovery Training in Age-related Disorders (PI: VanEldik) Role: Preceptor, Grant #:, Medical Oncology Fellowship Training Program (PI: Rosen) Mentoring/General Responsibilities related to the Graduate Program: Qualifications Part I exam: 4/04 Students rotating through the lab: John Norton, 4/04; Clarissa Schumacher 4/04, Sam MacBreyer 9/06, Kenji Wellman 1/07, Janet Pavese 7/07, Beth Sefton 9/07, Samantha Lin 1/08, Eric Voll 3/08, Kattie Harrington 9/08, Sankar Krishna 3/09, Michael Lin (medical student) 7/09, Andrea Glazier 8/09, Amanda Boe 1/10, Carrie Lee 3/10, Mark Sparrow (medical student) 7/10, Tushar Murthy 9/10, Juno Kim 1/11, Peter Jang (undergrad) 4/11, Thesis committee: Jeffrey Craft 8/03 (Linda VanEldik lab; MD/PhD candidate); defense 6/3/05 Thesis committee: Suneel M. Udanie 11/03 (MPH candidate) Thesis advisor: Clarissa Schumacher 6/2004, graduated 8/2007 Thesis advisor: Subhendu Mukhopadhyay 9/04 (Masters), graduated 9/06 Thesis committee (chair): John Norton (Sui Huang lab) 11/2004 Thesis committee: Iwonna Konieczna (Liz Eklund lab) 11/2004 Thesis committee: Ted Thurn (Gayle Woloschak lab) 3/2006 Thesis advisor: Kenji Wellman 6/2007 Thesis co-advisor (co-advisor Karl Scheidt): Rebecca Farmer 9/2007 (MSTP) Thesis committee: Ronald Smith (Bill Schnapper lab) 10/2007 Thesis advisor: Sankar Krishna (Masters in Bioinformatics), graduated 7/2008

18

Thesis advisor: Janet Pavese 6/2008 Thesis advisor: Eric Voll 6/2008 Thesis advisor: Sankar Krishna 6/2009 Thesis committee (chair for qualifications exam): Samantha Lin 4/2009 (Gestasios group) Thesis advisor: Michael Breen 7/2009 (MSTP) Thesis committee: Hans Arora 8/2009 Thesis committee: Ye Yuan 7/2010 Thesis committee (chair for qualifications exam): Ye Yuan 7/2010 (Woloschak group) Thesis committee: Carrie Lee (chair for qualification exam)11/2010 Thesis committee: Bethany Baumann 12/2010 Thesis committee: William Liu 5/2011 Thesis committee: Meghan Bliss-Moreau 5/2011 (Schnaper group) Thesis committee: Steven Johnson 2/2012 (chair for qualification exam) Thesis committee: Jung Kim 2/2012 (chair for qualification exam) Thesis committee: Yeqing (Angela) Yang 3/2013 Mentor (Chemistry of Life Processes, Chemistry:Biology Interface T32 Training Program):

Kristine Deibler (1st year graduate student 2013; Scheidt group) Thesis committee: Koshonna Brown 3/2014 Thesis committee: Rosa Ventrella 3/2014 Qualifications exam 5/2014 Thesis committee: (Chair of thesis committee) Rose Nyawira Njoroge 9/2015 K99 proposal mentor: Ted Laderas 4/2015

Mentoring/Current Laboratory Group: 11/2018-present Lianmei Zhao Post-doctoral Student

2018 Post-doctoral student, State Key Laboratory of Molecular Oncology and Cancer Hospital, Chinese Academy of Medical Sciences, Hebei Medical University

2014 Ph.D. Cancer Biology, Peking Union Medical College 2008 MS. Medical Immunology, Hebei Medical University 2005 BS. Clinical Medicine, Inner Mongolia University of Science and

Technology 11/2018-present Hyun-Kyung Ko Instructor

2013 Ph.D., Molecular and Cellular Biophysics and Biochemistry, Roswell Park, University of Buffalo

2006 Masters in Physics, Duke University 2002 Masters in Physics, Ewha Womans University, Seoul, Korea 2000 BS in Physics, Ewha Womans University, Seoul, Korea

2/2017-present Wenqi Li Senior Laboratory Technician

2010 Masters of Science, University of Kentucky

19

1/2016-present Graham Fowler Lab Technician

2015 Bachelor of Science, University of Maryland, Baltimore 3/2015-present Limin Zhang Post-doctoral student

2015 Masters of Science, Urology, Fudan University, Shanghai, China 2013 Bachelor of Science, Medicine, Jiaotong University, Shanghai, China

1/2015-present Abhinandan Pattanayak Lab Manager

Masters Degree 4/2013-present Ryan Gordon Research Assistant Professor Degree: 2009, Ph.D. Nutritional Biochemistry, University of North Carolina,

Chapel Hill Current Clinical Research Group: Swapnil Parmar, MD, Project Coordinator Kiara Siex, MPH, Senior Research Coordinator Former Clinical Research Group: Elizabeth Edwards, BS, Research Coordinator Mary Beth Tull, MS, Program Coordinator Silvia Skripkauskas, MPPA CCRC, Data Manager Benjamin Coatney, Protocol Coordinator

Former Laboratory Group: Summer 2018 Carlos Quihua

Tigard High School CURE Program Summer Intern

3/2015-3/2017 Aidan Toner Post-doctoral student

2015 PhD, Trinity University, Dublin, Ireland 9/2014-10/2015 Hu Zhang (co-primary thesis advisor, along with Prof Haowen Jiang) MD/PhD

candidate: Fudan University, supported by China Scholarship Council Shanghai, China 2012 Masters of Science, Urology, Fudan University, Shanghai, China 2010 Bachelor of Science, Medicine, Jiaotong University, Shanghai, China

Summer 2017 Kayla Machian Century High School

CURE Program Summer Intern Summer 2016 Alyssa Bailey

20

Jefferson High School CURE Program Summer Intern

10/2014-12/2015 Guan Xiao (co-primary thesis advisor, along with Prof. Lin Qi) PhD candidate:

Xiangya Hospital, Central South University; supported by China Scholarship Council Changsha, China

Summer 2015 Juanito Terrobias Portland High School

CURE Program Summer Intern 1/2013-1/2015 Guy Watkins Postdoctoral Student Degree: 2012, Ph.D. Pharmacology, Vanderbilt University Medical Center 12/07-1/2015 Sankar Krishna

Primary thesis advisor for graduate student, Northwestern University Degree: BS, Biotechnology, India

6/02-1/2015 Xiaoke Huang Laboratory Manager

Degree: M.D., Hunan Medical University (1982), China 11/2013-3/2015 Shurui Bian (primary thesis advisor) MS of Biotechnology Student: McCormick School of Engineering, Northwestern University

July, 2012 Bachelor of Science, Biological Science, Peking University Beijing, China

6/08-6/2014 Michael Breen Primary thesis advisor for MSTP graduate student, Northwestern University Degree: BS, Biology and Biotechnology, Worcester Polytechnic Institute-Main Program

6/08-6/2014 Eric Voll Primary thesis advisor for graduate student, Northwestern University Degree: BS, Chemistry, University of Virginia, Charlottesville Current 8/2014: Assistant Professor,

6/08-6/2014 Janet Pavese Primary thesis advisor for graduate student, Northwestern University Degree: BS, Biochemistry, University of Illinois, Champaign-Urbana Current 8/2014: Scientist, Abbott Molecular

10/2013-5/2014 Luke Zhan High School Student: Illinois Math Science Academy Current, 9/2014 Undergraduate Columbia University, Biochemistry and

Business 5/2010-8/2013 Irene Ogden Technician

Degree: MS (5/2010), Trinity College, Ireland 9/2011-2/2013 Wenzhe Liu, MD

21

Visiting Scholar: Oncology Department, Guangdong NO.2 Provincial People's Hospital, Guangzhou, China

Degree: 1998 M.S. in Oncology, The First Military Medical University, Guangzhou,

1991 M.D. China Medical University, Shenyang, China 8/03-2012 Li Xu Research Assistant Professor

Degree: M.D. (1993), Fourth Military Medical University, Xi’an, China Ph.D. (1999), Fourth Military Medical University, Xi’an,China Current, 9/2014, Associate Professor Fourth Military Medical University 6/2012 (summer) Ashley Ifeadike (CURE student)

Harvard University, Class of 2015 Degree Candidate in Biomedical Engineering

9/07-5/12 Rebecca Farmer Co-primary thesis advisor for MSTP graduate student, Northwestern University Degree: BS, Chemistry, University of Michigan

1/2011-8/2011 Sean Pruell Masters in Biotechnology Program

Degree: BS (5/2010), Biochemistry, Boston College Working for Abbott in Mass 9/2011

6/2010-8/2010 Jordan Shafran Stanford University BS Biology 6/2012 Summer research volunteer Current (2014) applying to graduate school 6/2010-10/2010 Mark Sparrow Dean’s Summer Research Program

M1 Northwestern University Medical Student Degree: BS, Cell and Molecular Biology, University of Illinois Champaign-Urbana

3/09-6/2010 Diarmuid Moran Post Doctoral Student Degree: Ph.D. (2005), Cell Biology, University of North Carolina Current 7/2013 Associate Director, Translational R&D Oncology at Quintiles

5/03-6/08 Yongzeng Ding Research Associate

Degree: M.D (1996), China Medical University, China Ph.D.(2003), Graduate School of Medicine, Kyoto University, Japan Current 6/2014, Attending physician Sisters Hospital, Buffalo

1/07-4/08 Kenji Wellman Primary thesis advisor for graduate student, Northwestern University

Degree: BS, Biochemistry, University of Ottawa 12/04-10/07 Minalini Lakshman

22

Post Doctoral Student Degree: Ph.D. Cell and Molecular Biology, University of Toronto Current Position: 11/2011: Visual Sonics (in Canada), Product research specialist; 11/2014: Manager, Scientific Operations

6/06-9/07 Matias Valsecchi Laboratory externship

Degree: MD, in his 4th year of internal medicine residency at the Hospital General de Agudos Juan A. Fernandez in Buenos Aires, Argentina Current position, 6/2014, Medical Oncologist, West Virginia

7/2003-9/06 Chen Shan Post Doctoral Student

Degree: Ph.D., National University of Singapore (2002) 9/04-9/06 Subhendu Mukhopadhyay Post Doctoral Student (Cancer Prevention Training Program)

Degree: Ph.D. Cell and Molecular Biology, Northwestern University Current 2012, Data Analysis, Abbott

4/04-8/07 Clarissa Schumacher-Craft Primary thesis advisor for graduate student, Northwestern University

Degree: BS Biochemistry, Belliot College Current 2013, Research Assistant Professor, Washington University

Summer 2006 Daniel Bradley Combined CURE and Drug Discovery Program laboratory summer

student Degree: Stanford University undergraduate, 2013-medical student at University of Southern California

8/01-1/2005 Lijo Simpson Internal Medicine Resident, Illinois Masonic Hospital

Degree: M.D., The All India Institute of Medical Sciences, New Delhi 11/00-6/02 Steven Hayes

Post Doctoral Fellow Degree: Ph.D., Biochemistry and Molecular Biology, University of

Illinois at Chicago Current 7/2014, VP R&D BellBrook labs Inc.

6/00-6/01 Karen Niguib Research Assistant Degree: M.S., Systems Engineering

B.S., Electrical Engineering, Oakland University 4/00-6/01 Brett Poisson Oncology Fellow/laboratory researcher Degree: M.D. 6/97-5/02 Yue-Qin Liu Post Doctoral Student Degree: M.D., China Medical University, Shenyang, China

23

Ph.D., Molecular Immunology, Cancer Institute of Chinese Academy of Medical Sciences and Peking Union Medical College Summer 2001 Kira Glover Combined CURE and Drug Discovery Program summer student Undergraduate in Chemical Engineering, Michigan State University Currently: Neuroscience graduate program, University of Colorado 6/99-4/01 Shuguang Wang Ph.D. Candidate Degree: Department of Statistics Northwestern University 1/00-6/00 Chadi Nabhan Oncology Fellow Degree: MD 7/93-7/98 Edward Kyle (technician) Technician Degree: BS, Microbiology, University of Maryland 12/96-7/98 W. Robert Hudgins Post Doctoral Student Degree: Ph.D., Biochemistry, George Washington University 1/97-6/98 Mariana Villegas Medical Student Degree: BS., Universidad Nacional de Cordoba, Facultad de Ciencias Medicas, Cordoba, Rep. Argentina 7/96-10/97 Kate Walshe Research Assistant Degree: BA, Fine Arts, Loyola College 8/96-9/97 Anuradha Kesari Research Assistant Degree: BA, Psychology, University of Virginia, Charlottesville 6/97-9/97 Seema Patel Summer Student Junior, Boston University, Boston, MA Summer 97 Rafiq Baksh Summer Intern Sophomore, University of Maryland, College Park, MD Summer 96 Jae Ryu Special Volunteer Degree: High School Senior and Member Leadership Program, Kennedy High School Summer 96 Valerie Makarick Cornell University Summer Student Senior, Cornell University Summer 96 William Corley Special Volunteer

24

Degree: B.S., Zoology, Howard University M.A., Administration, University District of Columbia Summer 96 Joseph Sweatmon

Special Volunteer McKinley High School Mentoring/Other: External Faculty Stephen I. Ekunwe (10/3-2005) Minority Junior Faculty Mentor

Degree: Ph.D. in Cell and Molecular Biology, Michigan State University Junior Faculty in Dept. of Cell and Molecular Biology, Jackson State University, Jackson, Mississippi

P&T Promotion and Tenure Committee Northwestern University: Ad Hoc Member (10/2008), Ad Hoc Chair (10/2010), Ad Hoc Member (10/2012) External Referee Promotion and Tenure Committee (6/2014), Department of Pharmaceutical and Biomedical Sciences at the University of Georgia, College of Pharmacy Faculty Mentor Northwestern University, Assigned by Dean’s Office to Jindan Yu, Ph.D.,

Assistant Professor (6/2014) Faculty Mentor Northwestern University, Assigned by Division Director to Young Chae,

MD, MPH, MBA, Assistant Professor (8/2014) Faculty Mentor For all Assistant Professors in the Division of Hematology/Oncology,

Knight Cancer Institute (1/2015) Teaching aids prepared 1. syllabus of genitourinary oncology for hematology/oncology fellows 2. syllabus for Cancer Chemoprevention graduate level course 3. syllabus for Cancer Prevention module, second year medical students cancer curriculum Funding Awards and grants received 1994 $40,000; Associate Investigator; Prostate Cancer Minority Studies Project; National Cancer Institute

FY 1995 $42,000; Associate Investigator; Prostate Cancer Minority Studies Project; National Cancer Institute 1/99-12/99 $10,000, Principal Investigator, Pharmacokinetics of

25

Genistein, a Tyrosine Kinase Inhibitors, National Center for Research Resources; NIH: RR000048-400391

4/99-3/03 Principal Investigator, National Cancer Institute Phase II Chemoprevention Master Agreement: N01-CN-85077-57

10/99-3/04 $1,071,008 (dir), Principal Investigator, Clinical Phase I

Multiple Dose Safety Study of the Combination of NAC and Oltipraz in Smokers, National Cancer Institute: NO1-CN-95037-44

10/99-9/03 Principal Investigator: National Cancer Institute Phase I

Chemoprevention Master Agreement: N01-CN-85080-70 1/00-1/04 $118,000, Principal Investigator: Phase I/II study of

taxol, estramustine and Quadramet in patients with hormone refractory prostate cancer; Grant in Aid from Berlex

4/00-8/00 $8,000, Principal Investigator: Role of endoglin in regulating prostate cancer cell adhesion, Prostate SPORE Seed Project; Cancer Center Core Grant (PI: Steven T. Rosen), National Cancer Institute P30 10/99-3/03

8/01-9/04 $82,861, Principal Investigator: A Phase II Study of

Mitoxantrone and ketoconazole and Hormone Therapy in Patients With Newly Diagnosed Metastatic Prostate Cancer, Grant in Aid from Immunex

5/01-7/03 $11,373,186 (total), Co-Director Prostate SPORE Grant

(PI: Chung Lee), National Cancer Institute: P50 CA90386-01

5/01-5/02 $44,350 (dir), Principal Investigator SPORE Pilot Project:

Role of endoglin in regulating prostate cancer cell adhesion, Prostate SPORE Pilot Project; National Cancer Institute: P50 CA90386-01

5/02-4/03 $50,000 (dir), Principal Investigator SPORE Pilot Project:

Regulation of prostate cancer cell adhesion; National Cancer Institute: P50 CA90386-01

3/03 $20,000 (total), Principal Investigator: Pilot studies for Regulation and modulation of prostate cell metastasis

26

Agency: H Foundation Basic Science Research Awards

9/02-8/05 $743,000 (total), $500,000 (direct), Principal Investigator: Molecular Correlates of Soy in Humans; National Cancer Institute: CA099263-01

5/03-4/04 $50,000 (dir), Principal Investigator: Genistein mediated regulation of prostate cell invasion, Prostate SPORE Pilot Project; National Cancer Institute: P50 CA90386-01

7/03-7/04 $11,373,186 (total), Interim-Director, Prostate SPORE,

National Cancer Institute: P50 CA90386-01 2/06-8/06 $50,000 (total), Principal Investigator:

Pilot Project from Core Grant funds to support submission of NIH multi-investigator grant. National Cancer Institute: P30 CA60553-06 (PI: Rosen)

5/04 – 5/07 $392,000 (total), Principal Investigator:

Prostate SPORE Mini Project; Modulation of p38 MAP kinase dependent motility in prostate cancer by the chemopreventive agent genistein. National Cancer Institute: P50 CA90386-01 (Lee: PI SPORE)

7/04 – 8/09 $637,500 (total), Principal Investigator: Regulation and

Modulation of Prostate Cell Metastasis (Veterans Administration Merit Review)

3/04-2/09 $2,000,719 (direct), Core Instructor, Postdoctoral training

program in cancer epidemiology and prevention (PI: Susan Gapstur); R25

6/06-5/10 $384,025 (direct to Bergan), Co-investigator on

Project: TiO2 Nanocomposites for Targeted Treatment and Imaging of Prostate Cancer (Project PI: Gayle Woloschak). This project is part of the Nanomaterials for Cancer Diagnostics and Therapeutics (Center of Cancer Nanotechnology Excellence; CCNE) grant (PI: Mirkin). National Institutes of Health: U54CA119341

6/03 – 5/12 $375,000 (to Bergan), Principal Investigator, Biomarker

identification core (funded as a subproject on Eastern Cooperative Oncology Group Cooperative Grant (PI: Fadlo Kuri); U10 CA37403)

27

11/08-10/11 Mentor, For Rebecca Farmer, F31 NIH pre-doctorial training grant, Discovery of molecular inhibitors of prostate cancer metastasis. (Note, grant score = 110).

1/09-12/10 $50,000 (Bergan/Scheidt; Co-PIs), Chemical “Disruptors”

of Metastasis: A New Approach to Prostate Cancer Prevention and Treatment, Dixon Translational Research Grant

9/09-8/13 $301,800 (total) Biospecimen Management Program (BMaP), co-investigator, American Recovery and Reinvestment Act (ARRA) award, supplement to U01 CA116875 (U01 PI: Steven Rosen)

8/01-7/13 $ (dir): Leader Cancer Prevention Program Cancer Center Core Grant (PI: Steven T. Rosen), National Cancer Institute: P30 CA60553-06 (NCI)

3/09-2/14 $1,312,500 (to Bergan), Principal Investigator, Project #4:

Modulation of prostate cancer cell motility by the chemopreventive agent genistein, Prostate SPORE, P50 CA90386 (SPORE PI, Chung Lee), National Cancer Institute.

9/12-8/14 $287,580 (total), PI of Biomarker Identification Core,

Prevention Center, NIH/NCI, ECOG-ACRIN CCOP Research Base Grant, U10 CA037403 (U10 PI: Comus)

9/08 – 8/14 $1,580,103 (total), Principal Investigator,

Genistein-mediated regulation of prostate cancer cell motility, R01 CA122985

9/31/03 – 9/14 $13,199,492 (total), Principal Investigator,

Center of Excellence for Chemoprevention Drug Development: Phase 1 and Phase 2 Clinical Trials of Cancer Chemopreventive Agents, NCI; N01-CN-35157,

funded studies: -phase 2, genistein, breast, primary endpoint: effect upon Ki67 in breast epithelial cells -phase 2, aspirin, colon, primary endpoint: effect upon light scattering spectroscopy parameters of colonic epithelium -Phase IIb Randomized Clinical Trial of the Retinoid Tazarotene in Renal Transplant Patients with Actinic Keratoses and a History of Non-Melanoma Skin Cancer (not implemented due to loss of drug supply) -phase 1, single dose methylselenium, prostate, toxicity & pharmacokinetics

28

-Phase IIb Trial of Anethole Dithiolethione (ADT) in Subjects with Bronchial Dysplasia (not implemented due to loss of drug supply) -phase 1, photodynamic therapy, head & neck, toxicity & pharmacokinetics -phase 2, PEG-5000, colon, primary endpoint: aberrant crypt foci formation -phase 2, 4-hydroxytamoxifen, determine if topical 4-OHT and oral tam have equivalent effects upon Ki67 in breast epithelial cells, and determine relative tissue levels of 4-OHT. -phase 1, erlotinib, in pre-malignant lung lesions, primary endpoint: EGFR phosphorylation -phase 1, multi-dose methylselenium, prostate, toxicity & pharmacokinetics -phase II, Inositol chemoprevention in colitis-associated dysplasia, primary endpoint: phosphorylation of β-catenin.

9/12-1/15 (left Northwestern) $10,104,174 (total), Principal Investigator, (hand PI off

when I left Northwestern) Cancer Prevention Agent Development Program: Early Phase Clinical Research, NCI; N01CN-2012-00035

funded studies (when Bergan served as PI): -pharmacokinetic study of oral versus transdermal selective progesterone receptor modulator, CDB-4124 in breast tissue -phase I study of inhaled Iloprost in former smokers -phase I study of berberine in inflammatory bowel disease (China-based clinical trial) -phase II trial of statin therapy to prevent recurrent pancreatitis

8/13-1/15 (left Northwestern) $ (dir): Leader Cancer Prevention Program Cancer Center Core Grant (PI: Steven T. Rosen), National Cancer Institute: P30 CA60553 (NCI)

6/13-12/14 $20,000 (dir): Mentor, A high-throughput screening

strategy to identify and validate inhibitors of mitogen-activated protein kinase kinase 4 (MEK4), Chicago Biomedical Consortium Supplemental Grant (PI: Sankar Krishna-Bergan’s graduate student)

4/14-3/19 $ (dir): Co-Investigator, (PQD5) imaging systemic tissue

injuries induced by anticancer drugs, NIH/NCI R01CA185214 (PI: Ming Zhao)

3/15-5/18 $59,880 (direct) Principal Investigator

Phase I study of berberine in inflammatory bowel disease (China-based clinical trial): NCI; N01CN-2012-00035

4/15-3/18 $ (dir): Co-Investigator, Discovery of Selective MAP2K4

Inhibitors to Target Metastasis, NIH/NCI R01 CA188015 (PI: Karl Scheidt)

29

9/15-8/17 $ (dir): Co-Investigator/PI for OHSU Study of newly

discovered immune cell in the blood and evaluation of its potential medical applications, Defense Advanced Research Projects Agency, DARPA-12-20-Open-BAA-FP-074; Role OHSU PI (PI: Cha-Mei Tang)

10/15-9/18 (extension to 9/19) $2,250,000 (total) Principal Investigator

Inhibiting prostate cancer cell motility, Department of Defense, Prostate Cancer Research Program, Laboratory-Clinical Transition Award: W81XWH-15-1-0527. Rank: 1%ile; i.e., of >100 applications submitted, only 1 was funded

10/15-9/19 $650,000 (direct) Principal Investigator Therapeutically targeting cancer cell motility, Veterans Administration Merit Award; IBX002842A Rank 1.5%ile

10/15-8/19 $(dir) Chair, Prevention Committee, ECOG-ACRIN; NCI Community Oncology Research Program (NCORP); NIH/NCI UG1CA189828; (PI: Lynne Wagner). 11/15-10/18 $15,000,000 (total) Co-Principal Investigator

Serial Measurement of Molecular Architecture and Response to Therapy (SMMART) Trials. Funded through a Prospect Creek Foundation Award; (PI: Joe Gray).

7/17-6/22 $ (dir): Co-Leader Translational Oncology Program Cancer Center Core Grant for the Knight Cancer Institute (PI: Brian Druker), National Cancer Institute: P30 CA69533 (NCI)

1/18-12/19 RMB 150,000: US Principal Investigator Apply Spectral

Imaging on esophageal cancer screening in Hebei Province (China PI: Haijun Zhang), Hebei Provincial Natural Science Foundation (grant #: 183977111D), China-foreign country collaboration grant

Grants awarded, but not accepted 12/02-11/05 $557,500 (total), $375,000 (direct), Principal Investigator:

Molecular Correlates of Soy in Humans; Department of Defense, Prostate Cancer Research Program, Idea

30

Development Grant, PC020418 (Grant was ranked in top 2%ile)

Selected Presentations, Seminars, and Talks 2/94 “Update on Toxicity and Efficacy Studies with the Natural Product Genistein”, United States Food and Drug Administration, Rockville, Maryland 2/94 “Genistein: Pharmacologic and Pharmacodynamic Considerations”, Rosewell Park Memorial Cancer Center, Buffalo, New York 4/94 “Electroporation of Lymphoma Cells with c-myc Antisense Oligonucleotides: A Model for Bone Marrow Purging”, American Association for Cancer Research, San Francisco, California 2/95 “Novel Therapeutic Approaches for the Treatment of Solid and Hematologic Malignancies”, H. Lee Moffitt Cancer Center, University of South Florida, Tampa, Florida 4/95 “Signal Transduction Modulation in Prostate Cancer”, Department of Hematology and Oncology, Emory University School of Medicine, Atlanta, Georgia 5/95 “The Role of Genistein in Prostate Cancer Prevention”, Wayne State University, Meyer L. Prentis Cancer Center, Detroit, Michigan 4/95 “Prostate Cancer Cell Adhesion is Associated With Focal Adhesion Kinase Integrin Complex Formation”, American Association for Cancer Research, Toronto, Canada 5/95 “Significant Activity by High Dose Tamoxifen in Hormone Refractory Prostate Cancer”, American Society for Clinical Oncology, Los Angeles, California 10/96 Inhibition of CML Cell Proliferation by an Aptamer to p210bcr-abl Kinase, Presidential Session, American Society for Bone Marrow Transplantation, San Diego, California 12/96 Ex Vivo Bone Marrow Purging with Oligonucleotides, First NIH Symposium on Therapeutic Oligonucleotides, Bethesda, Maryland 5/97 Signal Modulation in Neoplasia, Departments of Medical Oncology and Pharmaceutics, University of Colorado, Denver 8/97 Signal Modulation in Prostate Cancer: Cell Adhesion, Division of Clinical Sciences, NIH, Bethesda, Maryland 10/97 Oligonucleotide Based Non-Antisense Therapy for Neoplastic Disorders, NIH Workshop on Oligonucleotide Therapeutics, Bethesda, Maryland 2/98 Use of Oligonucleotides in the Ex Vivo Purging of Bone Marrow, Invited Speaker: United States Food and Drug Administration 2/98 Signal Modulation in Prostate Cancer, University Texas at Dallas, Dallas, TX

31

5/98 Targeted Therapy for Prostate Cancer, Hematology/Oncology Grand Rounds, Division of Hematology/Oncology, Northwestern University, Chicago, Ill 6/98 Therapeutic Implications of Modulation of Cell Adhesion in Prostate Cancer, Invited Speaker, Eli Lilly Co., Indianapolis, IN 1/99 Therapeutic Modulation of Cell Adhesion, Department of Pathology

Grand Rounds, Northwestern University 1/99 Regulation of Prostate Cancer Cell Adhesion, Tumor Cell Biology Series,

Lurie Cancer Center 8/99 Clinical Development of Genistein for Prostate Cancer, NCI Workshop on

Prostate Cancer Chemoprevention, Baltimore, MD. 1/2004 The Regulation of Prostate Cell Motility and its Therapeutic Modulation,

NCI Inter-Prostate SPORE meeting, Chicago, IL 3/2004 The Regulation of Prostate Cell Motility, Department of Medicine,

Northwestern University, Chicago, IL 11/2004 The Development of Cancer Chemopreventive Agents, Visiting Professor

for the 13th Annual San Antonio Caner Research Institute Symposium. 5/2006 Regulation of Prostate Cancer Cell Motility by TGFβ, Jesse Brown

Veterans Administration Research Seminar Series, University of Illinois at Chicago.

2/2007 Regulation of Prostate Cancer Cell Motility by TGFβ signaling pathways, Maine Medical Center Research Institute, Scarborough, ME.

11/2007 Inhibiting human prostate cancer metastasis by targeting the p38 MAP kinase-HSP27 pathway, Congress of International Drug Discovery Science and Technology (IDDST)-2007: Advances and Challenges Toward Major Diseases, Xi’an, China, Nov 2007

3/2008 Preventing Prostate cancer cell motility, Emory University 9/2008 Basic Cancer Biology, Education Session, NCI Alliance for

Nanotechnology in Cancer Investigators Meeting, Chicago, IL 11/2008 Discovering New Drugs to Inhibit Human Prostate Cancer Metastasis,

Educational Session AACR Frontiers in Cancer Prevention 2008, Washington, DC

12/2008 Stopping Prostate Cancer In Its Tracks, Science Lecture Series, Eppley Cancer Center, Omaha, NE

1/2009 Stopping Prostate Cancer In Its Tracks, Tumor Cell Biololgy Lecture Series, Northwestern University

11/2009 Preventing Progression to a Metastatic Phenotype in Prostate Cancer, Eastern Cooperative Oncology Group, Baltimore, MD

3/2010 Inhibiting Prostate Cancer Metastasis, Translational Research Symposium, Chicago, IL

11/2010 Phase 2 study of genistein in men with prostate cancer, Clinical Trials Session, American Association of Cancer Research 2010 Frontiers in Cancer Prevention Annual Meeting

11/2011 Using Chemistry to Probe Biology, Biopharmaceutical Sciences Symposium, University of Illinois at Chicago

2/2012 Protein-Driven Strategies for Drug Discovery, Meeting Chair, Center for

32

Molecular Innovation and Drug Discovery Symposium 6/2012 Therapeutically targeting carcinogenesis, Boston, MA, Eastern

Cooperative Oncology Group - American College of Radiology Imaging Network meeting

5/2012 Using soy to inform anti-metastatic therapeutic strategies, Keynote Speaker, Annual Conference American Council for Medicinally Active Plants

6/2012 Translating Science Between Bench and Clinic, Grand Rounds, Xijing Hospital, Fourth Military Medical University, Xi’an, China

2/2013 Soy and Prostate Cancer, 6th International Congress on Vegetarian Nutrition, Loma Linda University, Loma Linda, CA

4/2013 Therapeutically Targeting Carcinogenesis, University of Illinois at Chicago

5/2013 Therapeutically Targeting the Tumor-Microenvironment Interaction, 6th Annual World Cancer Congress-2013, Xi’an, China

5/2013 Therapeutically Targeting Carcinogenesis, Xijing Hospital, Fourth Military Medical University, Xi’an, China

5/2013 Transforming research findings into beneficial therapy for patients. Third Regional Hospital, Guangzhou, China

5/2013 Cancer Molecular Pharmacolgy and Drug Discovery. Sun-yat Sen University, Guangzhou, China

5/2013 Targeting prostate cancer carcinogenesis. Department of Urology, Fudan University, Shanghai, China

11/2013 Translating Basic Research into Clinical Trials and Better Therapy. Jingzhou 2013 International Oncology Conference, Jingzhou, China

11/2013 Therapeutically Targeting Prostate Cancer Metastasis. Jiaotong University, Xi’an, China

3/2014 Translating Basic Research into Clinical Trials and Better Therapy, Oregon Health & Science University, Portland, Oregon

4/2014 Therapeutically Targeting Carcinogenesis, American Association of Cancer Research, Molecular Epidemiology Working Group Town Hall Meeting, San Diego, California

5/2014 Therapeutically Targeting Carcinogenesis, Fox Chase Cancer Center, Philadelphia, Pennsylvania

6/2015 Translating Basic Research Discoveries into the Clinic, YiRen Hospital, Wuxi, China

11/2015 Next Steps in Cancer Prevention, National Cancer Institute, Cancer Prevention Think Tank, Bethesda, Maryland

11/2015 Cancer Prevention, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network, Orlando, Florida

1/2016 Therapeutically Targeting Prostate Cancer Cell Motility, University of Washington

10/2016 Precision Medicine and Cancer Treatment, “100 Hospital Presidents Visiting Program—the 3rd Sino-US Hospital Leadership Symposium”,

Health Human Resources Development Center, National Health and Family Planning Commission, P. R. China, Beijing, China

33

10/2016 The Translational Oncology Program, NCI Site Visit for renewal of the Cancer Center Support Grant for the Knight Cancer Institute, Portland, OR

11/2016 The Role of Imaging in Cancer Prevention, Keynote Address: Scientific Planning Committee, ECOG-ACRIN, Orlando, Fla

5/2017 What is coming and what is not: early phase trials, agents, biomarkers in Cancer Prevention, ECOG-ACRIN, Washington, DC

5/2017 Testing New Ideas in the Clinic, Beijing University of Chinese Medicine, Beijing, China

5/2017 Chemoprevention and Transforming Basic Science into the Clinic, Shijiazhuang University, Shijiazhuang, China

10/2017 A Way Forward for Cancer Chemoprevention: Think Local, Oregon Health & Science University, Portland, Oregon

11/2017 Precision Oncology, Opening Speaker, OHSU Precision Oncology Symposium, Portland, Oregon

11/2017 Precision Oncology, Grand Rounds, Shijiazhuang Cancer Hospital, Shijiazhuang, China

12/2017 Cancer Chemoprevention: Pathways Forward, University of Florida Gainesville, Gainesville, Florida

7/2018 Application of Spectral Imaging Technology in Esophageal Cancer Early Detection, Hebei Provence Leading Scientific and Technological Talents Conference, San Jose, California

9/2018 Cancer Prevention: Pathways Forward, Hebei International Forum on Theory and Practice of Cancer Prevention and Control, Shijiazhaung,

China 9/2018 Opening Ceremony Speaker, Hebei International Forum on Theory and Practice of Cancer Prevention and Control, Shijiazhaung, China Research Clinical Protocol Responsibilities.

Current: • Protocol Chair/Chair Cancer Prevention Committee (ECOG-ACRIN): Double Blinded

Randomized Phase II Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers. (EA8184)

• Co-Investigator (ECOG-ACRIN Principle Investigator) Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III (PACES) (S0820; SWOG)

• Principal Investigator: Serial Measurements of Molecular and Architectural Response to Therapy (SMMART) Trial (OHSU IRB #: S00015588)

• Principal Investigator: Molecular Mechanisms of Tumor Evolution and Resistance to Therapy (OHSU IRB #: 00011862)

34

• Principal Investigator: Evaluation of Cancer Associated Macrophage-Like (CAML) and Circulating Tumor Cells (CTC) in Cancer Patients (OHSU IRB #: IRB00011862)

• Protocol Chair: Phase I trial of Berberine in subjects with ulcerative colitis (NCI2014-03-01; NWU2014-03-01; CT.gov#: NCT02365480)

Prior: • Principal Investigator: Molecular analysis of prostate tissue (STU00103263) • Principal Investigator: A Phase I Trial of Inhaled Iloprost for the Prevention of Lung Cancer

in Former Smokers (NCI2013-02-01; NWU2013-02-01; CT.gov#: NCT02237183) • Principal Investigator: Intra-mammary distribution of transdermal telapristone versus oral

telapristone: a randomized window trial in women undergoing mastectomy (NCI2013-01-03. NWU2013-01-03; CT.gov#: NCT02314156)

• Principal Investigator: developing novel assays to detect circulating cancer cells in the blood • Co-investigator/Scientific PI: Phase 2 trial of genistein in men with circulating prostate

cancer cells (CT.gov #: NCT01126879) • Principal Investigator: Myo-Inositol Chemoprevention in Colitis-Associated Dysplasia

(NCI09-13-02, NWU09-13-02) • Principal Investigator: Phase I Multiple Dose Study of 12-Week Treatment by Se-Methyl-L-

Cysteine (MSC) and L SeMet in Adult Males (NCI09-4-03, NWU09-4-03) • Principal Investigator: A Phase I Study of Erlotinib in Patients with Premalignant Lesions of

the Lung (NCI 08-11-01, NWU 08-11-01) • Principal Investigator: Polyethylene Glycol for ACF Reduction and Biomarker Modulation in

Individuals with CRC Risk (NCI06-8-01, NWU06-8-01) • Principal Investigator: Spectral Markers in Aspirin Chemoprevention of Colonic Neoplasia

(NCI 04-2-03, NWU 04-2-03) • Principal Investigator: Pre-surgical Phase IIb trial of transdermal 4-Hydroxytamoxifen vs.

oral tamoxifen in women with ductal carcinoma in situ of the breast (NCI 07-9-02, NWU 07-9-02)

• Principal Investigator: A Phase I Trial of ALA PDT for Treatment of Oral Leukoplakia (NCI 05-05-01, NWU 05-05-01)

• Principal Investigator: A Retrospective Review of the Recruiting Practices for NCI04B3: Significance of Accrual Source and Subject Demographics

• Principal Investigator: Phase I Study of Single Oral Dose of Se-methyl-seleno-L-cysteine (MSC) in Adult Men (NCI04-4-02, NWU04-4-02)

• Principal Investigator: Phase IIB Trial of G-2535 (Unconjugated Isoflavones-100) in Women at High Risk for Breast Cancer (NCI 03-1-04, NWU03-1-04)

• Northwestern Principal Investigator: The Selenium and Vitamin E Chemoprevention Trial (SELECT) (Coordinating Institution: Southwest Oncology Group)

• Principal Investigator: A Phase II Study of Genistein in Patients with Localized Prostate Cancer

• Principal Investigator: A Phase I/II study of Taxol and Estramustine followed by Quadramet in Advanced Prostate Cancer (Investigator initiated protocol (supported by Berlex)

• Co- Investigator: Phase II trial of the Proteasome Inhibitor PS-341 in Patients with Metastatic Breast Cancer (PI: William Gradishar, Northwestern University).

35

• Principal Investigator: Phase II Trial of Mitoxantrone and Ketoconazole for Hormone Refractory Prostate Cancer (supported by Immunex)

• Principal Investigator: Clinical Phase I Multiple-Dose Safety Study of Oltipraz in Smokers (NCI contract study)

• Principal Investigator: A Phase 1 Trial of Genistein, a Tyrosine Kinase Inhibitor • Northwestern Principal Investigator: Randomized Study of Procrit (Epoetin alpha) Vs. no

Procrit on Clinical Outcomes in Advanced Hormone Refractory Prostate Cancer (Coordinating Institute: Johns Hopkins University, Baltimore, MD)

• Principal Investigator: A Phase I/II Study of High Dose Tamoxifen in Combination with Vinblastine in Patients with Hormone Refractory Prostate Cancer.

• Principal Investigator: A Phase II Trial of High Dose Tamoxifen in the Treatment of Patients with Prostate Cancer.

• Associate Investigator: A Randomized Phase II Study of Oral Thalidomide in Patients with Hormone Refractory Prostate Cancer.

• Associate Investigator: A Phase II Study of Oral CAI in Patients with Androgen-Independent Prostate Cancer.

• Associate Investigator: A Phase 1 Study of Oral COL-3 (NSC 683551), a Matrix Metalloproteinase Inhibitor, in Patients with Hormone-Refractory Prostate Cancer.

• Associate Investigator (former Protocol Chairman): A Phase 1 Study of Infusional Paclitaxel with the P Glycoprotein Antagonist PSC 833.

• Associate Investigator: A phase I/II study of continuous intravenous infusion of PSC-833 and vinblastine in patients with metastatic renal cancer.

• Associate Investigator: A Phase II Trial of Suramin, Leuprolide, and Flutamide in Patients with Prostate Cancer.

• Associate Investigator: A Phase I Trial of Suramin in Patients with Advanced Solid Tumors. • Associate Investigator: Treatment of Patients with Androgen-Resistant Prostate Cancer with

a Combination of Aminoglutethimide and Suramin (phase II study).

Military Service (6/92-7/98) 6/92-6/93: United States Public Health Service Commissioned Officer O-3 (Lt.) 6/93-6/98: United States Public Health Service Commissioned Officer O-4 (Lt. CDR), honorable discharge. Additional Professional Activities January 1987 Volunteer work General Medical Clinics Honduras, Central America January 1989 Volunteer work General Medical Clinics Ecuador, South America 1991-1993 Volunteer physician

36

Zacchaeus Medical Clinic 1329 N Street, NW Washington, DC 6/99 Consultant, Eli Lilly Co.

Development Strategy for Prostate Cancer Therapeutics 9/99 Member, Amgen External Advisory Board 10/99 Consultant, Berlex Corporation 6/01 Board Member, Dalandis C. Neely II Sickle Cell Trait Foundation 8/13-present Third Coast Therapeutics, Inc., Co-Founder, Co-Owner, Member,

Board of Directors and Chief Scientific Officer

Selected Continuing Education Activities 4/93 Using Animals in Intramural Research, National Institutes of

Health, Bethesda, MD 11/97 Advanced Recombinant DNA: Techniques and Applications, American Type Culture Collection; one-week full time. 4/00, 7/06 Using Animals in Research, Northwestern University 6/00…9/08 NIH, humans’ subjects training 4/03 HIPAA training 4/03-present All VA Research training modules (~10-20 per year), including

human subjects, and good clinical practice 2/04 Board of Internal Medicine recertification requirements for

medical oncology 1/2009 VA-Suicide Risk Management 6/2009 No FEAR (Notification & Federal EmployeeAntidiscrimination &

Retaliation) Act 6/2009 Protected Peer Review Process (Members/Reviewers of PPR

Committees) 6/2009 VA Peer Review Process for All Clinical Providers 6/2009 VA-Ethics in Health Care 6/2009 Process for All Clinical Providers 6/2009 VA-Complete Medical Quality Assurance Records Title 38 6/2009 VA-Complete Anticoagulation Education for Prescribers 6/2009 VA-Complete Prevention of Sexual Harassment 10/2009 VHA Privacy policy 10/2009 Incident command system, FEMA 10/2009 VA Information Security Awareness and

Rules of Behavior 11/2009 CITI 12/2009 VA Ethics Most Wanted 8/2010 Basic Cardiac Life support 1/2011 For IRB members: CITI Training; VA Information

37

Security Awareness; VA Information Security for R&D Personnel; VHA Privacy Training.

1/2011 Mentor Training for Clinical and Translational Science Researchers

5/2012 VA Suite of Annual Training. 9/13/2012 Northwestern Conflict of Interest Training 5/2013 VA Suite of Annual Training. 5/2014 VA Suite of Annual Training. 5/2014 ABIM Medical Oncology Recertification 3/2015 CITI training 3/2015 Oregon Health & Science University training suite 9/2015 VA Suite of Annual Training. 10/2015 CITI training VA, working with research animals; working with

the IACUC 9/2016 VA Suite of Annual Training. 9/2017 VA Suite of Annual Training. 5/2018 Unconscious Bias Foundations, OHSU 6/2018 CITI Responsible conduct of research 6/2018 OHSU Integrity booster 6/2018 CITI Human Subjects Research refresher 9/2018 VA Suite of Annual Training. Certifications NCI/CTEP Registered Investigator since 1992 (CTEP Investigator ID is 'IVR-23959'); status is ACTIVE through 3/27/2020 Board eligible in Internal Medicine: date certified 9/1990 Board certified in Medical Oncology: date certified 11/1993, 11/2004, 4/2014 Basic Cardiac Life Support: 8/2010, 10/2013 Advanced Cardiac Life Support: prior UPIN#: F82279 NPI#: 1871569640 Publications

Peer Reviewed Publications 1. Richard Burt, Raymond Bergan, Bruce A. Chabner. HTLV-1 associated diseases. Internal Medicine (1991); 12(4), 31-40. 2. Raymond Bergan, Wyndham Wilson. Spotting pulmonary disease in the cancer patient. Internal Medicine (1992); 13(9), 56-65.

38

3. Angelo Rosolen, Edward Kyle, Christine Chavany, Raymond Bergan, E T Kalman, Robert Crouch, and Len Neckers. Effect of over-expression of bacterial ribonuclease H on the utility of antisense MYC oligonucleotides in the monocytic leukemia cell line U937. Biochimie 75, 79-67 (1993).

4. Raymond Bergan, Yvette Connell, Brigid Fahmy, Len Neckers. Electroporation enhances c-myc antisense oligodeoxynucleotides efficacy. Nucleic Acids Research 21(15), 3567-73, 1993http://www.ncbi.nlm.nih.gov/pubmed/8346033

5. Raymond Bergan, Yvette Connell, Brigid Fahmy, Edward Kyle, Len Neckers. Aptameric inhibition of the p210bcr-abl tyrosine kinase by oligodeoxynucleotides of defined sequence and backbone structure. Nucleic Acids Research. 22(11), 2150-2154, 1994. http://www.ncbi.nlm.nih.gov/pubmed/8029025

6. Figg, W.D., Cooper, M.R., Thibault, A., Headlee, D., Humphrey, J., Bergan, R.C., Reed, E., Sartor, O. Acute renal toxicity associated with suramin in the treatment of prostate cancer. Cancer 74(5), 1612-1614, 1994. http://www.ncbi.nlm.nih.gov/pubmed/8062193 7. Figg, W.D., Sartor, O., Cooper, M.R., Alain Thibault, A., Bergan, R.C., Dawson, N.A., Reed, E., Myers, C.E.. Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. American Journal of Medicine 98(4), 412-414, 1995. http://www.ncbi.nlm.nih.gov/pubmed/7535978

8. Raymond C. Bergan, Yvette Connell, Edward Kyle, Len Neckers. Inhibition of protein-tyrosine kinase activity in intact cells by the aptameric action of oligodeoxynucleotides. Antisense Research and Development 5(1), 33-38, 1995. http://www.ncbi.nlm.nih.gov/pubmed/7542047

9. Nancy A. Dawson, Michael Cooper, William D. Figg, Donna Headlee, Alain Thibault, Raymond C. Bergan, Anne Tompkins, Seth M. Steinberg, Edward A. Sausville, Charles E. Myers, and Oliver Sartor. Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables. Cancer 76 (3), 453-62, 1995. http://www.ncbi.nlm.nih.gov/pubmed/8625127 10. Raymond Bergan, Edward Kyle, Phuongmai Nguyen, Jane Trepel, Christian Ingui, and Len Neckers. Genistein-stimulated adherence of prostate cancer cells is associated with the binding of focal adhesion kinase to beta-1-integrin. Clinical and Experimental Metastasis, September 14(4), 389-398, 1996. http://www.ncbi.nlm.nih.gov/pubmed/8878413

11. Raymond Bergan, Frances Hakim, Gretchen N. Schwartz, Edward Kyle, Rose Cepada, Janet M. Szabo, Daniel Fowler, Ronald Gress, and Len Neckers. Electroporation of synthetic oligodeoxynucleotides: a novel technique for ex vivo bone marrow purging. Blood 88 (2), 731-741, 1996. http://www.ncbi.nlm.nih.gov/pubmed/8695822

39

12. Edward Kyle, Len Neckers, Chris Takimoto, Gregory Curt, and Raymond Bergan. Genistein-induced apoptosis of prostate cancer cells is preceded by a specific decrease in focal adhesion kinase activity. Molecular Pharmacology 51 (2), 193-200 1997. http://www.ncbi.nlm.nih.gov/pubmed/9203623

13. Raymond Bergan. Ex vivo bone marrow urging with oligonucleotides. Antisense and Nucleic Acid Drug Development, 7 (3), 251-255, 1997.

14. R.C. Bergan, R. Walls, W.D. Figg, N. Dawson, D. Headlee, A. Tompkins, S. Steinberg, E. Reed. Similar clinical outcomes in African-American and caucasian males, treated with suramin for metastatic prostate cancer. Journal of the National Medical Association, 89(9), 1-7 1997. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2608263/

15. N.A. Dawson; W.D. Figg; M.R. Cooper; O. Sartor; R.C. Bergan; A.M. Senderowicz; S.M. Steinberg; A. Tompkins; B.Weinberger B; E.A. Sausville; E. Reed; C.E. Myers. Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer. Journal of Clinical Oncology, 15 (4), 1470-1477, 1997. http://www.ncbi.nlm.nih.gov/pubmed/9193342

16. Nancy Dawson, William D. Figg, Otis W. Brawley, Raymond Bergan, Michail R. Cooper, Adrian Senderowicz, Donna Headlee, Seth M. Steinberg, Melissa Sutherland, Nicholas Patronas, Edward Sausville, Eddie Reed, and Oliver Sartor. Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal. Clinical Cancer Research, 4, 37-44, 1998. http://www.ncbi.nlm.nih.gov/pubmed/9516950 17. Gretchen N. Schwartz, Yue-Qin Liu, John Tisdale, Kate Walshe, Daniel Fowler, Ronald Gress, Raymond C. Bergan. Growth inhibition of chronic myelogenous leukemia cells by ODN-1, an aptameric inhibitor of p210bcr-abl tyrosine kinase activity. Antisense & Nucleic Acid Drug Development, 8(4), 329-339, 1998. http://www.ncbi.nlm.nih.gov/pubmed/9743470

18. Christian Rohlff, Mikhail Blagosklonny, Edward Kyle, Anuradha Kesari, Isaac Yi Kim, David J. Zelner, Francis Hakim, Raymond Bergan. Prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and induction of p21waf1/cip1. The Prostate, 37, 51-59, 1998. http://www.ncbi.nlm.nih.gov/pubmed/9721069

19. Alain Thibault, William D. Figg, Raymond C. Bergan, Richard M. Lush, Charles E. Myers, Anne Tompkins, Eddie Reed, Dvorit Samid. A phase II study of 5 AZA-2’deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer. Tumori; 84(1), 87-89, 1998. http://www.ncbi.nlm.nih.gov/pubmed/0009619724

20. William D. Figg, Sangeeta Raje, Kenneth S. Bauer, Anne Tompkins, David Venzon, Raymond Bergan, Alice Chen, Michael Hamilton, James Pluda and Eddie Reed. Pharmacokinetics of thalidomide in an elderly prostate cancer population. Journal of Pharmaceutical Sciences; 88(1):121-5, 1999. http://www.ncbi.nlm.nih.gov/pubmed/9874712

40

21. Raymond C. Bergan, Eddie Reed, Charles E. Myers, Donna Headlee, Otis Brawley, Hea-Kyoung Cho, W. Douglas Figg, Anne Tompkins, W. Marston Linehan, David Kohler, Seth M. Steinberg, and Mikhail Blagosklonny. A phase II study of high dose tamoxifen in patients with hormone refractory prostate cancer. Clinical Cancer Research, 5(9):2366-73, 1999. http://www.ncbi.nlm.nih.gov/pubmed/10499606 22. Mikhail V. Blagosklonny, Yutaka Chuman, Raymond C. Bergan and Tito Fojo. Mitogen activated protein kinase pathway is dispensable for microtubule-active drug-induced Raf-1/Bcl-2 phosphorylation and apoptosis in leukemia cells. Leukemia, 13: 1028-1036, 1999. http://www.ncbi.nlm.nih.gov/pubmed/10400418

23. Chung Lee, Lynn Janulis, Kenneth Ilio, Ali Shah, Irwin Park, Samuel Kim, Vincent Cryns, Michael Pins and Raymond Bergan. In vitro models of prostate apoptosis: clusterin as an antiapoptotic marker. The Prostate, 9: 21-24, 2000. http://www.ncbi.nlm.nih.gov/pubmed/11056498

24. Yue-Qin Liu, Edward Kyle, Ronald Lieberman, James Crowell, Gary Kelloff, and Raymond Bergan. Focal adhesion kinase (FAK) phosphorylation is not required for FAK-β-1-integrin complex formation. Clinical and Experimental Metastasis, 18(3):203-12, 2000. http://www.ncbi.nlm.nih.gov/pubmed/11315093

25. Yue-Qin Liu, Edward Kyle, Ronald Lieberman, Frank Frausseaue, Susan Topalian, Frances Hakim and Raymond Bergan. Prostate cancer chemoprevention agents exhibit selective activity against early stage prostate cancer cells. Prostate Cancer and Prostatic Diseases, 4, 1-11, 2001. http://www.ncbi.nlm.nih.gov/pubmed/12497043

26. Yue-Qin Liu and Raymond Bergan. Improved intracellular delivery of oligonucleotides by square wave electroporation. Antisense and Nucleic Acid Drug Development, 11(1), 7-14, 2001. http://www.ncbi.nlm.nih.gov/pubmed/11258623

27. Chico I, Kang MH, Bergan R, Abraham J, Bakke S, Meadows B, Rutt A,, Robey R, Choyke P, Merino M, Goldspiel B, Smith T, Steinberg S, Figg WD, Fojo T, Bates S. Phase I study of infusional paclitaxel in combination with the P-Glycoprotein antagonist PSC 833. Journal of Clinical Oncology, 19(3):832-842, 2001. http://www.ncbi.nlm.nih.gov/pubmed/11157037 28. Borko D. Jovanovic, Shuguang Huang, Yuequin Liu, Karen N. Naguib and Raymond C. Bergan. A simple analysis of gene expression and variability in gene arrays based on repeated observations. American Journal of Pharmacogenomics, 1(2): 145-152, 2001. http://www.ncbi.nlm.nih.gov/pubmed/12174675

29. Susan E. Bates, Min H. Kang, Bervely Meadows, Susan Dakke, Peter Choyke, Maria Merino, Barry Goldspiel, Isagani Chico, Tom Smith, Clara Chen, Rob Robey, Raymond Bergan, William D. Figg, Tito Fojo. A phase 1 study of infusional vinblastine in combination with the Pgp antagonist PSC 833 (Valdospar). Cancer, 92(6): 1577-90, 2001.

41

http://onlinelibrary.wiley.com/doi/10.1002/1097-0142(20010915)92:6%3C1577::AID-CNCR1484%3E3.0.CO;2-H/full

30. Yuequin Liu, Borko Jovanovic, Michael Pins, Chung Lee and Raymond C. Bergan. Over expression of endoglin in human prostate cancer suppresses cell detachment, migration and invasion. Oncogene, 21(54):8272-8281, 2002. http://www.ncbi.nlm.nih.gov/pubmed/12447690

31. Steven A. Hayes, Xiaoke Huang, Suman Kambhampati, Leonidas C. Platanias, and Raymond C. Bergan. p38 MAP kinase modulates Smad dependent changes in human prostate cell adhesion. Oncogene, 22, 4841-4850, 2003. http://www.ncbi.nlm.nih.gov/pubmed/12894225

32. Christopher H. Takimoto, Kira Glover, Xiaoke Huang, Steven A. Hayes, Lilia Gallot, Mary Quinn, Borko D. Jovanovic, Alla Shapiro, Leticia Hernandez, Andrew Goetz, Victor Llorens, Ronald Lieberman, James A. Crowell, Brett A. Poisson, Raymond C. Bergan. Phase I pharmacokinetic and pharmacodynamic analysis of unconjugated soy isoflavones administered to individuals with cancer. Cancer Epidemiology, Biomarkers and Prevention, 12, 1213-1221, 2003. http://www.ncbi.nlm.nih.gov/pubmed/14652284 33. Ximing J. Yang, Jun Sugimura, Maria S. Tretiakova, Kyle Furge, Greg Zagaja, Mitchell Sokoloff, Michael Pins, Raymond Bergan, Walter M. Stadler, Nicholas J. Vogelzang, Bin Tean Teh. Gene expression profiling of renal medullary carcinoma: potential clinical relevance. Cancer. 100(5):976-85, 2004. http://www.ncbi.nlm.nih.gov/pubmed/14983493 34. Lijo Simpson, Xiang He, Michael Pins, Xiaoke Huang, Steven C. Campbell, Ximing J. Yang, Elizabeth J. Perlman and Raymond C. Bergan, Renal Medullary Carcinoma and ABL gene amplification, Journal of Urology, 173(6): 1883-8, 2005. http://www.ncbi.nlm.nih.gov/pubmed/15879768 Altmetric = 3; 60%ile 35. Xiaoke Huang, Shan Chen, Yueqin Liu, Li Xu, Dilip K. Deb, Leonidas C. Platanias, and Raymond C. Bergan, Genistein inhibits p38 MAP kinase activation, MMP-2, and cell invasion in human prostate, Cancer Research 65(8), 3470-3478, 2005. http://www.ncbi.nlm.nih.gov/pubmed/15833883 Altmetric = 3; 61%ile 36. Michael J. Kelley, Elizabeth M. Glaser, James E. Herndon II, Frank Becker, Yu-Jing Zhang, Regina M. Santella, Steven G. Carmella, Stephen S. Hecht, Lilia Gallot, Lawrence Schilder, James A. Crowell, Marjorie Perloff, Rodney J. Folz, Raymond C. Bergan, Safety and Efficacy of Weekly Oral Oltipraz in Chronic Smokers, Cancer Epidemiology Biomarkers and Prevention, 14(4):892-9, 2005 http://www.ncbi.nlm.nih.gov/pubmed/15824161

37. John Eklund, Mark Kozloff, Joy Vlamakis, Alexander Starr, Margaret Mariott, Lilia Gallot, Borko Jovanovic, Lawrence Schilder, Erwin Robin, Michael Pins, and Raymond C. Bergan. Phase II Study of Mitoxantrone and Ketoconazole for Hormone Refractory Prostate Cancer. Cancer, 2006; 106(11):2459-2465. http://www.ncbi.nlm.nih.gov/pubmed/16615097

42

38. Li Xu, Shan Chen, and Raymond Bergan. MAPKAPK2 and HSP27 are downstream effectors of TGFß-mediated matrix metalloproteinase type 2 activation and cell invasion in human prostate cancer. Oncogene, 2006; 25(21): 2987-98. http://www.ncbi.nlm.nih.gov/pubmed/16407830 Altmetric = 6; 75%ile 39. Yongzeng Ding, Li Xu, Shan Chen, Borko D. Jovanovic, Irene B. Helnowski, David L. Kelly, William J. Catalona, Ximing J. Yang, Michael Pins, Vijayalakshmi Ananthanarayanan and Raymond C. Bergan. Characterization of a method for profiling gene expression in cells recovered from intact human prostate tissue using RNA linear amplification. Prostate Cancer and Prostatic Diseases, 2006; 9(4):379-91. http://www.ncbi.nlm.nih.gov/pubmed/16786039 Altmetric = 3; 66%ile 40. Li Xu and Raymond Bergan. Genistein inhibits MMP-2 activation and prostate cancer cell invasion by blocking TGFβ-mediated activation of the MAPKAPK2-HSP27 pathway. Molecular Pharmacology, 2006; 70(3): 869-77 http://molpharm.aspetjournals.org/content/70/3/869?related-urls=yes&legid=molpharm;70/3/869

41. Engel, R. H., Brown, J. A., Von Roenn, J. H., O'Regan, R. M., Bergan, R., Badve, S., Rademaker, A., and Gradishar, W. J. A Phase II Study of Single Agent Bortezomib in Patients with Metastatic Breast Cancer: A Single Institution Experience. Cancer Invest: 1-5, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17952740 Altmetric = 6; 62%ile 42. Clarissa S. Craft, Diana Romero, Calvin P.H. Vary, and Raymond C. Bergan. Endoglin inhibits prostate cancer motility via activation of the ALK2-Smad1 pathway. Oncogene, 26:7240-7250, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17496924 Altmetric = 3; 61%ile 43. Kim YL, Jacobs DR, Gross MD, Bergan RC, Gann PH, Liu K, Gapstur SM. Associations of serum carotenoid levels with serum insulin-like growth factor (IGF)-1 and IGF-binding protein (IGFBP)-3 levels in black men and white men. Cancer Epidemiology Biomarkers and Prevention, I16(12):2781-3, 2007. http://www.ncbi.nlm.nih.gov/pubmed/18086788 44. Yongzeng Ding, Li Xu, Borko Jovanovic, Irene B. Helenowski, David L. Kelly, William J. Catalona, Ximing J. Yang, Michael Pins, and Raymond C. Bergan. The methodology used to measure differential gene expression affects the outcome, The Journal of Biomolecular Techniques, 18(5):321-330, 2007. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2392989/

45. Minalini Lakshman, Li Xu, Vijayalakshmi Ananthanarayanan, Joshua Cooper, Chris H. Takimoto, Irene Helenowski, and Raymond C. Bergan. Dietary genistein inhibits metastasis of human prostate cancer, Cancer Research, 68: 2024-2032, 2008 (selected for press release) http://www.ncbi.nlm.nih.gov/pubmed/18339885. Altmetric = 13; 75%ile

43

46. Clarissa S. Craft, Li Xu, Diana Romero, Calvin P.H. Vary, and Raymond C. Bergan. Genistein induces phenotypic reversion of endoglin deficiency in human prostate cancer cells. Molecular Pharmacology, 73(1):235-42, 2008. http://www.ncbi.nlm.nih.gov/pubmed/17951357. Altmetric = 3; 61%ile 47. Salida Mirzoeva, Nam D. Kim, Karen Chiu, Carrie Franzen, Raymond C. Bergan, and Jill C. Pelling. Inhibition of HIF-1 alpha and VEGF expression by the chemopreventive bioflavonoid apigenin is accompanied by Akt inhibition in human prostate carcinoma PC3-M cells. Molecular Carcinogenesis, 47(9):686-700, 2008. http://www.ncbi.nlm.nih.gov/pubmed/18240292 Altmetric = 3; 61%ile 48. Tatjana Paunesku, Tianyi Ke, Rohan Dharmakumar, Nicole Mascheri, Aiguo Wu, Barry Lai, Stefan Vogt, Jörg Maser, Kenneth Thurn, Barbara Szolc-Kowalska, Andrew Larson, Raymond C Bergan, Reed Omary, Debiao Li, Zheng-Rong Lu, and Gayle E. Woloschak. Gadolinium conjugated TiO2-DNA oligonucleotide nanoconjugates show prolonged intracellular retention period and T1-weighted contrast enhancement in Magnetic Resonance images. Nanomedicine. 2008 Sep; 4(3):201-7. http://www.ncbi.nlm.nih.gov/pubmed/18567541 Altmetric = 6; 75%ile 49. Kenneth T. Thurn, Tatjana Paunesku, Aiguo Wu, Eric M. B. Brown, Barry Lai, Stefan Vogt, Jo¨rg Maser, Mohammed Aslam, Vinayak Dravid, Raymond Bergan, and Gayle Woloschak. Labeling TiO2 Nanoparticles with Dyes for Optical Fluorescence Microscopy and Determination of TiO2-DNA Nanoconjugate Stability. Small, 5(11):1318-25, 2009 http://www.ncbi.nlm.nih.gov/pubmed/19242946 Altmetric = 6; 75%ile 50. Li Xu, Yongzeng Ding, William J. Catalona, Ximing Yang, Wayne F. Anderson, Borko Jovanovic, Kenji Wellman, Jaqueline Killmer, Xiaoke Huang, Karl A. Scheidt, R. Bruce Montgomery, and Raymond C. Bergan. MEK4 Function, Genistein Treatment, and Invasion of Human Prostate Cancer Cells. Journal of the National Cancer Institute, 101(16):1141-55, 2009, PMID:19638505 http://www.ncbi.nlm.nih.gov/pubmed/19638505. Altmetric = 3; 64%ile 51. Diana Romero, Aleksandra Terzic, Barbara A. Conley, Clarissa Craft, Borko Jovanovic, Raymond Bergan, and Calvin P.H. Vary. Endoglin phosphorylation by ALK2 contributes to the regulation of prostate cancer cell migration. Carcinogenesis, 31(3):359-66, 2010. PMID: 19736306 http://www.ncbi.nlm.nih.gov/pubmed/19736306 52. Rebecca Farmer, Margaret M. Biddle, Antoinette E. Nibbs, Xiaoke Huang, Raymond C. Bergan, and Karl A. Scheidt. Concise syntheses of the abyssinones and discovery of new inhibitors of prostate cancer and MMP-2 expression. ACS Medicinal Chemistry Letters 1(8):400-405. 2010; PMCID 2992379. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2992379/

44

53. Minalini Lakshman, Xiaoke Huang, Vijayalakshmi Ananthanarayanan, Borko Jovanovic, Yueqin Liu, Clarissa S. Craft, Diana Romero, Calvin P.H. Vary, Raymond C. Bergan. Endoglin suppresses human prostate cancer metastasis. Clinical and Experimental Metastasis. 28(1), 39-53, 2010. PMCID: 3046557 http://www.ncbi.nlm.nih.gov/pubmed/20981476.

54. Janet M. Pavese, Rebecca L. Farmer, and Raymond C. Bergan. Inhibition of cancer cell invasion and metastasis by genistein. Cancer and Metastasis Reviews. 29(3):465-482, 2010. PMCID: 2933845 http://www.ncbi.nlm.nih.gov/pubmed/20730632. Altmetric = 5; 75%ile 55. James R. Marshall, Clement Ip, Karen Romano, Gerald Fetterly, Marwan Fakih, Borko Jovanovic, Marjorie Perloff, James Crowell, Warren Davis, Renee French-Christy, Alexander Dew, Margerie Coomes, Raymond Bergan. Methyl Selenocysteine: single-dose pharmacokinetics in men. Cancer Prevention Research, Cancer Prevention Research. 2011, 4(11):1938-44. PMID: 21846796. http://www.ncbi.nlm.nih.gov/pubmed/21846796; Bergan PI of NCI award that funded this study. Altmetric = 3; 64%ile 56. Diana Romero, Christine O'Neill, Aleksandra Terzic, Liangru Contois, Kira Young, Barbara Conley, Raymond Bergan, Peter Brooks, and Calvin Vary. Endoglin regulates cancer-stromal cell interactions in prostate tumors. Cancer Research, 2011, 71(10):3482-93. PMCID: 3096740. http://www.ncbi.nlm.nih.gov/pubmed/21444673.

57. Breen MJ, Bergan RC. Endoglin suppresses human prostate cancer metastasis. UroToday, Beyond the Abstract, June 29, 2011, Internet]: http://www.urotoday.com/prostate-cancer-1014/beyond-the-abstract- endoglin-suppresses-human-prostate-cancer-metastasis-by-michael-breen-md-phd-candidate-and-raymond-bergan-md.html.

58. Seema Khan, Robert Chatterton, Michelle Bryk , Oukseub Lee, David Ivancic, Richard Heinz, Carola M. Zalles, Irene B. Helenowski, Borko Jovanovic, Adrian A. Franke, Maarten C. Bosland, Jun Wang, Nora Hansen, Kevin Bethke, Alexander Dew, Margerie Coomes, Raymond Bergan. Soy Isoflavone Supplementation for Breast Cancer Risk Reduction: A Randomized Phase II Trial. Cancer Prevention Research 2012, 5(2): 309-19; PMCID: 3333836 (Cited by AACR Publications Office as one of the most highly-cited Cancer Prevention Research articles published in 2012); http://www.ncbi.nlm.nih.gov/pubmed/22307566; Bergan PI of NCI award that funded this study. Altmetric = 28; 95%ile 59. Alexander Dew, Seema Khan, Christie Babinski, Nancy Michel, Marie Heffernan, Stephanie Stephan, Neil Jordan, Borko Jovanovic, Paula Carney and Raymond Bergan. Recruitment Strategy Cost and Impact on Minority Accrual to a Breast Cancer Prevention Trial. Clinical Trials: Journal of the Society for Clinical Trials, 10(2):292-9, 2013 PMID:23321266; http://www.ncbi.nlm.nih.gov/pubmed/23321266.

45

60. Jin HJ, Zhao JC, Ogden I, Bergan RC, Yu J. Androgen receptor-independent function of FoxA1 in prostate cancer metastasis. Cancer Res. 15;73(12):3725-36, 2013. doi: 10.1158/0008-5472.CAN-12-3468. PMID: 23539448; http://www.ncbi.nlm.nih.gov/pubmed/23539448. Altmetric = 5; 75%ile 61. Janet M. Pavese, Irene M. Ogden, Raymond C. Bergan. A Novel Orthotopic Murine Model of Human Prostate Cancer Metastasis. The Journal of Visual Experiments (79), e50873, doi:10.3791/50873 (2013); PMCID 3814297; www.jove.com/video/50873/an-orthotopic-murine-model-of-human-prostate-cancer-metastasis. Altmetric = 11; 75%ile 62. Samuel H. Light, Sankar N. Krishna, Raymond C. Bergan, Arnon Lavie, Wayne F. Anderson. Crystal structure of a type II dehydroquinate dehydratase-like protein from Bifidobacterium longum, J Structural and Functional Genomics, Mar;14(1):25-30, 2013, PMCID: 3878977; http://www.ncbi.nlm.nih.gov/pubmed/23539270.

63. A phase I trial of aminolevulinic acid-photodynamic therapy for treatment of oral leukoplakia. Wong SJ, Campbell B, Massey B, Lynch DP, Cohen EE, Blair E, Selle R, Shklovskaya J, Jovanovic BD, Skripkauskas S, Dew A, Kulesza P, Parimi V, Bergan RC, Szabo E. Oral Oncol. 49(9):970-6, 2013, PMID: 23845699; http://www.ncbi.nlm.nih.gov/pubmed/23845699; Bergan PI of NCI award that funded this study.

64. Michael J. Breen, Diarmuid M. Moran, Wenzhe Liu, Xiaoke Huang, Calvin P.H. Vary and Raymond C. Bergan. Endoglin-mediated suppression of prostate cancer invasion is regulated by activin and bone morphogenetic protein type II receptors. PLoS One 8(8):e72407, 2013. PMCID: 3742533; http://www.ncbi.nlm.nih.gov/pubmed/23967299. Altmetric = 3; 64%ile 65. Sankar N Krishna, Chi-Hao Luan, Rama Mishra, Karl Scheidt, Wayne Anderson, and Raymond Bergan, A fluorescence-based thermal shift assay identifies inhibitors of mitogen activated kinase kinase 4. PLoS ONE 8(12): 2013; PMCID 3855329; http://www.ncbi.nlm.nih.gov/pubmed/24339940. Altmetric = 4; 75%ile 66. Melissa A. Simon, Erika E. de la Riva, Raymond Bergan, Carrie Norbeck, June McKoy, Piotr Kulesza, XinQi Dong, Julian Schink, Linda Fleisher. Improving Diversity in Cancer Research Trials: The Story of the Cancer Disparities Research Network. Journal of Cancer Education, 29(2), 366-74, 2014; PCMID: 4029870; http://www.ncbi.nlm.nih.gov/pubmed/24519744.

67. Daniel L Adams, Stuart S Martin, Katherine R Alpaugh, Monica Charpentier, Susan Tsai, Raymond Bergan, Irene Ogden, William Catalona, Saranya Chumsri, Cha-Mei Tang, Massimo Cristofanilli, Circulating Giant Macrophages as a potential biomarker of solid tumors.

46

Proceedings of the National Academy of Sciences 111 (9), 3514-9, 2014; PCMID: 3948254; http://www.ncbi.nlm.nih.gov/pubmed/24550495. Altmetric = 23; 75%ile 68. Janet M. Pavese, Irene M. Ogden, Eric A. Voll, Xiaoke Huang, Borko Jovanovic, Li Xu and Raymond C. Bergan. Mitogen-activated protein kinase kinase 4 (MEK4) promotes human prostate cancer metastasis. PLoS One, 9(7), e102289, 2014, PMCID: 4096757; http://www.ncbi.nlm.nih.gov/pubmed/25019290. Altmetric = 1; 50%ile 69. Eric A Voll, Irene M Ogden , Janet M Pavese, XiaoKe Huang, Li Xu, Borko D Jovanovic, and Raymond C Bergan. Heat shock protein 27 regulates human prostate cancer metastasis. Oncotarget, 5(9), 2648-63, 2014; PCMID: 4058034; http://www.ncbi.nlm.nih.gov/pubmed/24798191.

70. Hossain, M.; Wang, Xin; Bergan, Raymond; Jin, Jian-Ping. Decreases in h2-calponin in prostate cancer cells increase proliferation, migration and the dependence of cell adhesion on substrate stiffness. FEBS Open Bio 4:627-36, 2014, PMID: 25161871; doi.org/10.1016/j.fob.2014.06.003. Altmetric = 4; 73%ile 71. Oukseub Lee, Katherine Page, David Ivancic, Irene Helenowski, Vamsi Parimi, Megan Sullivan, Julie Margenthaler, Robert Chatterton, Borko Jovanovic, Barbara Dunn, Brandy Heckman-Stoddard, Kathleen Foster, Miguel Muzzio, Julia Shklovskaya, Silvia Skripkauskas, Piotr Kulesza, David Green, Nora Hansen, Kevin Bethke, Jacqueline Jeruss, D.Allred, Raymond Bergan and Seema Khan. A randomized phase II presurgical trial of transdermal 4-Hydroxytamoxifen gel versus oral tamoxifen in women with ductal carcinoma in situ of the breast. Clinical Cancer Research, 20(14), 3672-82, 2014; PCMID: 4101910; http://www.ncbi.nlm.nih.gov/pubmed/25028506 (Selected by AACR for Press Release; Bergan PI of NCI award that funded this study. Altmetric = 54; 95%ile 72. Janet M. Pavese and Raymond C. Bergan. Circulating tumor cells exhibit a biologically aggressive cancer phenotype accompanied by selective resistance to chemotherapy. Cancer Letters, 352(2), 179-86, 2014; PCMID: 4139115; http://www.ncbi.nlm.nih.gov/pubmed/25016063. 73. Xiao Xiao, Zhiguo Liu, Rui Wang, Jiayin Wang, Song Zhang, Xiqiang Cai, KaichunWu, Raymond C. Bergan, Li Xu, Daiming Fan. Genistein suppresses FLT4 and inhibits human colon cancer metastasis. Oncotarget 2015, 20;6(5):3225-39; PMID: 25605009; DOI: 10.18632/oncotarget.3064. Altmetric = 1; 50%ile 74. Hou L, Joyce BT, Gao T, Liu L, Zheng Y, Penedo FJ, Liu S, Zhang W, Bergan R, Dai Q, Vokonas P, Hoxha M, Schwartz J, Baccarelli A. Blood Telomere Length Attrition and Cancer

47

Development in the Normative Aging Study Cohort.; EBioMedicine. 2015 Apr 13;2(6):591-6. doi: 10.1016/j.ebiom.2015.04.008. eCollection 2015 Jun.; PMID: 26288820; Role: co-author. Altmetric = 29; 95%ile 75. Hemant K. Roy, Vladimir Turzhitsky, Ramesh Wali, Andrew J. Radosevich, Borko Jovanovic, Gary Della’Zanna, Asad Umar, David T. Rubin, Michael J. Goldberg, Laura Bianchi, Mart De La Cruz, Andrej Bogojevic, Irene B. Helenowski, Luz Rodriguez, Robert Chatterton, Silvia Skripkauskas, Katherine Page, Christopher R. Weber, Xiaoke Huang, Ellen Richmond, Raymond C. Bergan*, Vadim Backman* (*contributed equally). Spectral Biomarkers for Chemoprevention of Colonic Neoplasia: A Placebo-Controlled Double-Blinded Trial with Aspirin. Gut 2017 Feb;66(2):285-292. doi: 10.1136/gutjnl-2015-309996; PMID: 26503631; Role: Bergan PI of NCI award that funded this study. Altmetric = 1 76. Graff JN, Alumkal JJ, Drake CG, Thomas GV, Redmond WL, Farhad M, Cetnar JP, Ey FS, Bergan RC, Slottke R, Beer TM. Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget. 2016, 7(33):52810-52817. doi: 10.18632/oncotarget.10547, PMID: 27429197. Altmetric = 34; 95%ile 77. James R. Marshall, Raymond Burk, Rochelle Payne Ondracek, Kristine E. Hill, Marjorie Perloff, Warren Davis, Roberto Pili, Saby George and Raymond Bergan. Selenomethionine and methyl selenocysteine: multiple-dose pharmacokinetics in selenium-replete men. Oncotarget. 2017 Apr 18;8(16):26312-26322. doi: 10.18632/oncotarget.15460. PMID: 28412747; Bergan PI of NCI award that funded this study. Altmetric = 2; 50%ile 78. Kristine K. Deibler, Rama K. Mishra, Matthew R. Clutter, Aleksandar Antanasijevic, Raymond Bergan, Michael Caffrey and Karl A. Scheidt. A Chemical Probe Strategy for Interrogating Inhibitor Selectivity Across the MEK kinase Family. ACS Chem Biol. 2017 May 19;12(5):1245-1256. doi: 10.1021/acschembio.6b01060. Epub 2017 Mar 20. PMID: 28263556. Altmetric = 1 79. Ramesh K Wali, Laura Bianchi, Sonia Kupfer, Mart De La Cruz, Borko Jovanovic, Christopher Weber, Michael J. Goldberg, L.M. Rodriguez, Raymond Bergan, David Rubin, Mary Beth Tull, Ellen Richmond, Beth Parker, Seema Khan, Hemant K Roy. Prevention of colonic neoplasia with Polyethylene Glycol: a short term placebo-controlled double-blinded trial. PLoS One. 2018 Apr 4;13(4):e0193544. doi: 10.1371/journal.pone.0193544. eCollection 2018. PMID: 29617381; Bergan PI of NCI award that funded this study. Altmetric = 1 80. Li Xu, Ryan Gordon, Rebecca Farmer, Abhinandan Pattanayak, Andrew Binkowski, Xiaoke Huang, Michael Avram, Sankar Krishna, Eric Voll, Janet Pavese, Juan Chavez, James Bruce, Andrew Mazar, Antoinette Nibbs, Wayne Anderson, Lin Li, Borko Jovanovic, Sean Pruell, Matias Valsecchi, Giulio Francia, Rick Betori, Karl Scheidt and Raymond Bergan. Precision

48

Therapeutic Targeting of Human Cancer Cell Motility. Nature Communications, 9(1):2454, 2018. PMID: 29934502; PMCID: PMC6014988; DOI: 10.1038/s41467-018-04465-5. URL: https://www.nature.com/articles/s41467-018-04465-5 *WIRED magazine cited this study (https://www.wired.com/story/why-your-doctor-should-also-be-a-scientist/), stating “Such monumental discoveries are the specialty of the physician-scientist.” Altmetric = 265; 99%ile for all journals, 98%ile for Nature Communications

81. Lu E, Thomas GV, Chen Y, Wyatt AW, Lloyd P, Youngren J, Quigley D, Bergan R, Bailey S, Beer TM, Feng FY, Small EJ, Alumkal JJ. DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer. J Natl Compr Canc Netw. 2018 Aug;16(8):933-937. doi: 10.6004/jnccn.2018.7020. PMID: 30099369. Altmetric = 2; 50%ile 82. Steven E. Johnson, Andrey Ugolkov, Chad R Haney, Gennadiy Bondarenko, Lin Li, Emily A Waters, Raymond Bergan, Andy Tran, Thomas V O'Halloran, Andrew P. Mazar and Ming Zhao. Whole-body imaging of cell death provides a systemic, minimally invasive, dynamic and near-real time indicator for chemotherapeutic drug toxicity. Clinical Cancer Research, In Press 2018, doi: 10.1158/1078-0432.CCR-18-1846. [Epub ahead of print]; PMID: 30420445. Altmetric = 4; 61%ile 83. Zahi I Mitri, Swapnil Parmar, Brett Johnson, Annette Kolodzie, Jamie M Keck, Max Morris, Alexander Guimaraes , Brooke R Beckett, Uma Borate, Charles D Lopez, Kathleen A Kemmer, Joshi J Alumkal, Tom M Beer, Christopher L Corless, Gordon B Mills, Joe W Gray, Raymond C Bergan. Implementing a Comprehensive Translational Oncology Platform: From Molecular Testing to Actionability. Journal of Translational Medicine, 16(1):358-68, 2018; doi: 10.1186/s12967-018-1733-y; PMID: 30551737. Altmetric = 3; 60%ile 84. Greeshma Thrivikraman, Avathamsa Athirasala, Ryan Gordon, Raymond Bergan, Douglas R. Keene, James M. Jones, Hua Xie, Brian Wingender, Laurie Gower, Jack L. Ferracane, Luiz E. Bertassoni. Directed intrafibrillar mineralization of cell-laden collagen for rapid fabrication of bone models with biomimetic nanostructure, vasculature and function. Nature Communications, 2019, In Press.

85. Hu Zhang, Ryan Gordon, Wenqi Li, Ximing Yang, Abhinandan Pattanayak, Graham Fowler, Limin Zhang, William J. Catalona, Yongzeng Ding, Li Xu, Xiaoke Huang, Borko Jovanovic, David L. Kelly, Haowen Jiang* and Raymond Bergan* Genistein treatment duration effects biomarkers of cell motility in human prostate. PLoS One. 2019 Mar 27;14(3):e0214078. doi: 10.1371/journal.pone.0214078. eCollection 2019; https://doi.org/10.1371/journal.pone.0214078

86. Y Li, Y Guo, Z Feng, R Bergan, B Li, Y Qin, L Zhao, Z Zhang, M Shi. Involvement of the PI3K/Akt/Nrf2 signaling pathway in resveratrol-mediated reversal of drug resistance in HL-60/ADR cells. Nutrition and Cancer, In Press 2019.

49

87. Daniel L. Adams, Massimo Cristofanilli, Steven H. Lin, Raymond C. Bergan, Thai H. Ho, Jeffrey R. Marks, R. Katherine Alpaugh, William Catalona, Stuart S. Martin, Saranya Chumsri, Elizabeth J Hager, Melinda G. Hollingshead, Cha-Mei Tang, Susan Tsai, Diane K. Adams. Cancer associated polyploid cells in circulation act as accomplices in the spread of solid tumors. Submitted. 88. Xiangmei Zhang, Zhenzhen Zhang, Miao Cao, Beichen Liu, Motomi Mori, Shiuh-Wen Luoh, Raymond Bergan, Yueping Liu, Zhensheng Li, Yunjiang Liu. A randomized parallel controlled phase II trial of recombinant human endostatin added to neoadjuvant chemotherapy for stage III breast cancer, Submitted

89. Julie N. Graff, Joshi J. Alumkal, George V. Thomas, Reid F. Thompson, Amy E. Moran, Mary A. Wood, Raymond C. Bergan, Charles G. Drake, Rachel E. Slottke, Amy E. Moran, Tomasz M. Beer. Phase II, Single-Arm Study of Pembrolizumab with Enzalutamide in Men with Metastatic Castration Resistant Prostate Cancer Progressing on Enzalutamide Alone. Submitted.

90. Karl A. Scheidt, Kristine K. Deibler, Gary E. Schiltz, Matthew R. Clutter, Rama K. Mishra, Purav Vagadia, Matthew O’Connor, Mariam D. George, Ryan Gordon, Graham Fowler and Raymond Bergan. Synthesis and Biological Evaluation of 3-Arylindazoles as Selective MEK4 Inhibitors. ChemMedChem, 2019, Feb 1. doi: 10.1002/cmdc.201900019. [Epub ahead of print] PMID: 30707493 Altmetric = 2; 51%ile 91. Limin Zhang, Abhinandan Pattanayak, Wenqi Li, Graham Fowler, Ryan Gordon* and Raymond C. Bergan. Multi-functional therapy: inhibiting cancer cell motility, growth and interaction with the microenvironment. Provisional Acceptance, Molecular Cancer Therapeutics, 2019. 92. Li Xu, Yujie Zhang,Xianmin Xue, Jie liu,Zhengshan Li, Guang-Yu Yang, Ying Song,Yan Pan, Yueyun Ma,Sijun Hu, Aidong Wen, Luz Rodriquez, Borko Jovanovic, Mary Beth Tull, Seema Khan, Ying Cao, Raymond Bergan* and Kaichun Wu* A Phase I Trial of Berberine in Chinese with Ulcerative Colitis, Submitted. Bergan PI of NCI award that funded this study and Study Chair. 93. Limin Zhang, Christopher Amling, Haowei Jiang and Raymond C. Bergan. Differential clinical presentation characteristics between Chinese and US men with prostate cancer. Manuscript in Preparation.

94. Allen Li, Jamie Keck, Swapnil Parmar, Annette Kolodzie, Chris Corless, Brett Johnson, Joe Gray, Raymond Bergan, Gordon B. Mills, Zahi Mitri. Serial Biopsies Reveal Extensive Evolution of Subtypes Among Metastases in a Breast Cancer Patient. Manuscript in Preparation.

95. Rama K. Mishra, Kristine K. Deibler, Matthew R. Clutter, Purav P. Vagadia, Matthew O’Connor, Gary E. Schiltz, Raymond Bergan and Karl A. Scheidt. Modeling MEK4 Kinase Inhibitors Through Perturbed Electrostatic Potential (ESP) Charges. Manuscript in Preparation

50

Peer Reviewed Invited Articles

96. Raymond Bergan, Doyle H. Waggle, Stephen K. Carter, Ivan Horak, and William Slichenmyer. Tyrosine Kinase Inhibitors and Signal Transduction Modulators: Rationale and Current Status as Chemopreventive Agents for Prostate Cancer. Urology, Apr;57 (4 Suppl 1):77-80, 2001. http://www.ncbi.nlm.nih.gov/pubmed/11295600 Altmetric = 3; 61%ile 97. Li Xu, Sophia S. Wang, Megan A. Healey, Jessica M. Faupel-Badger, Jason A. Wilken, Tracy Battaglia, Eva Szabo, Jenny T. Mao and Raymond C. Bergan. The Ninth Annual American Association of Cancer Research International Conference on Frontiers in Cancer Prevention Research. Cancer Prevention Research, 4(4): 616-21, 2011. PMCID 21464034; http://www.ncbi.nlm.nih.gov/pubmed/21464034

98. Janet M Pavese, Sankar N Krishna and Raymond C Bergan, Genistein Inhibits Human Prostate Cancer Cell Adhesion, Invasion, and Metastasis. The American Journal of Clinical Nutrition, 100, 431S-436S, 2014, PMID: 24871471; http://www.ncbi.nlm.nih.gov/pubmed/24871471 Altmetric = 2; 55%ile 99. Sankar Krishna and Raymond C. Bergan, Therapeutic modulation of human prostate cell motility and metastasis. Future Medicinal Chemistry, 6(2), 223–239, 2014; PCMID: 24467245; http://www.ncbi.nlm.nih.gov/pubmed/24467245 Altmetric = 4; 73%ile 100. Luai Al-Rabadi and Raymond C. Bergan. A Way Forward for Cancer Chemoprevention: Think Local. Invited Review, Cancer Prevention Research, 10(1):14-35, 2017, doi: 10.1158/1940-6207.CAPR-16-0194; PMID: 27780807 Note: this work was the basis for NCI developing the SBIR RFA: NIH/NCI 374, Novel Approaches for Local Delivery of Chemopreventive Agents Altmetric = 4; 66%ile 101. Zhenzhen Zhang, Raymond Bergan, Jackilen Shannon, Christopher G. Slatore, Gerd Bobe, Yumie Takata. The Role of Cruciferous Vegetables and Isothiocyanates for Lung Cancer Prevention: Current Status, Challenges and Future Research Directions. Molecular Nutrition and Food Research, 2018 Apr 16:e1700936. doi: 10.1002/mnfr.201700936. [Epub ahead of print, PMID: 29663679 Altmetric = 1 102. A Way Forward for Cancer Chemoprevention: Using Multiple Factors to Refine Individual Risk. Invited Review, Cancer Prevention Research, Zhenzhen Zhang, Tomi Mori and Raymond C. Bergan Manuscript In Preparation.

51

Letters to the Editor

103. Raymond C. Bergan and Len Neckers. How Do Antisense Oligodeoxynucleotides Inhibit the Growth of Chronic Myelogenous Leukemia Cells? Blood 87;4019, 1996. http://www.ncbi.nlm.nih.gov/pubmed/8611740 104. Khan SA, Chatterton RT, Bergan R. Soy Isoflavones for Breast Cancer Risk Reduction--Response. Cancer Prev Res. 2012, PMID: 22693168

Books and Invited Articles

105. Leonard M. Neckers, Daniel Geselowitz, Christine Chavany, Luke Whitesell and Raymond Bergan. Antisense Efficacy: Site-Restricted In Vivo and Ex Vivo Models. In :Methods in Molecular Medicine: Antisense Therapeutics: S. Agrawal (Ed.), Humana Press Inc. 1995, Totowa, N.J., pages 47 56. 106. Cho-Chung YS, Beaucage S, Bergan R, Marquez V, Neckers L, Torrence PF. Presentations from the second NIH symposium on therapeutic oligonucleotides - Introduction. ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, 8 (2): 113-114 APR 1998.

107. Cancer Chemoprevention: Raymond Bergan (Ed), Kluwer Academic Publications, Inc., 2001, Boston, MA.

108. Nabhan and Raymond Bergan. Chemoprevention of Prostate Cancer. In: Cancer Chemoprevention: Raymond Bergan (Ed), Kluwer Academic Publications, Inc., 2001, Boston, MA, volume 106: pages 103-136.

109. Borko D. Jovanovic and Raymond C. Bergan. Coefficient of variation for ratios and for gene expression intensities for “treatment” and “control” single line PC3-M cells. Proceedings JSA, Biopharmaceutical Section, American Statistical Association, paper 312, 2001.

110. Borko D. Jovanovic, Shuguang Huang, Yuequin Liu, Karen N. Naguib and Raymond C. Bergan. An analysis of gene array data related to cell adhesion and prostate cancer. In: Biostatistical Applications in Cancer Research, ed. Craig Beam; Kluwer Academic publishers, Norwell, Massachusetts, Cancer Treatment and Research, 113, 91-111, 2002. http://www.ncbi.nlm.nih.gov/pubmed/12613352

111. Borko D. Jovanovic, Raymond C Bergan, and Warren A. Kibbe. Some Aspects of Analysis of Gene Array Data. In: Biostatistical Applications in Cancer Research, ed. Craig Beam; Kluwer Academic publishers, Norwell, Massachusetts, Cancer Treatment and Research, 113, 71-89, 2002. http://www.ncbi.nlm.nih.gov/pubmed/12613351

112. Raymond C. Bergan. Cancer Chemoprevention. The Journal, 8(2), 4-12, 2002.

52

113. Borko D. Jovanovic, Irene B. Helenowski, Marlos A.G. Viana, and Raymond C. Bergan. On Calculating False Positive Rates in Gene Expression. Proceedings JSA, Biopharmaceutical Section, American Statistical Association, 2002.

114. Jovanovic BD, Helenowski IB, Rademaker AW, Bedford DF, Bergan RC: Some statistical issues in the study of variability of gene expression with applications in prostate cancer study. Proceedings of the First Sino-International Symposium on Probability, Statistics and Qualitative Management. Taipei, Taiwan, ROC, June 6, 2004, pp. 51-60. October 2004.

115. Janet M. Pavese and Raymond C. Bergan, Natural compounds from soy and their benefits against prostate cancer. The Soy Connection, 2012; http://www.soyconnection.com/sites/default/files/Soy_Health_and_Nutrition_Newsletter_Fall_12_.pdf

Selected Abstracts

116. Steven A. Hayes and Raymond Bergan. p38 MAP kinase is required for transforming growth factor beta-mediated cell adhesion in metastatic prostate cancer cells. Proceedings American Association of Cancer Research, 43, 22, abstract # 114, 2002. 117. Author order: Mark Kozloff, Joy Vamakis, Eryn Ferdman, Margarett Mariott, Lilia Gallot, Borko Jovanovic, Lawrence Schilder, Raymond Bergan. Phase II Trial of Mitoxantrone and Ketoconazole for Hormone Refractory Prostate Cancer. Proceedings of American Society for Clinical Oncology, 20, 153b, abstract #: 2364, 2002.

118. Kelley, MJ, Folz, RJ, Glaser, EM,1 Herndon, JE, Crowell, JA, Perloff, M, Santella R, Ferdman E, Gallot L, Becker R, Bergan, RC. Phase I chemoprevention trial of oltipraz in smokers. Proceedings of American Society for Clinical Oncology, , abstract In Press, 2003.

119. Xiang He, Michael Pins, Lijo Simpson, and Raymond C. Bergan. ABL is amplified in renal medullary carcinoma. Proceedings of the National Society for Histochemistry, In Press 2003.

120. Jovanovic BD, Helenowski IB, Viana MAG, Bergan RC: "Logonormal distribution, false positive and false negative error rates in gene screening". 2003 Proceedings of the American Statistical Association, Biopharmaceutical Section (CD-ROM), paper 167. Alexandria, VA. 2003.

121. Xiaoke Huang, Shan Chen, Yueqin Liu, Li Xu, and Raymond C. Bergan. Genistein inhibits TGF beta-mediated induction of MMP-2 and cell invasion in human prostate cancer by blocking phosphorylation of P38 MAP kinase. Proceedings American Association of Cancer Research, 45, 427, abstract # 1860, 2004

122. Lijo Simpson, Xiang He, Michael Pins, Xiaoke Huang, Steven C. Campbell , Ximing J. Yang and Raymond C. Bergan. ABL gene amplification is associated with Renal Medullary

53

Carcinoma. Proceedings of American Society for Clinical Oncology , abstract 1246, In Press, 2004.

123. S. L. Arnsmeier, S. Spies, D. Shervin, M. Pins, R. C. Bergan. Phase I/II study of taxane and estramustine with samarium (Quadramet) in patients with hormone refractory prostate cancer. Proceedings of American Society for Clinical Oncology , abstract 3074, In Press 2004.

124. J. Brown, J. Von Roenn, R. O’Regan, R. Bergan, S. Badve, A. Rademaker, S. Feehan, J. Petersen, M. Patton, W. Gradishar. A phase II study of the proteasome inhibitor PS-341 in patients (pts) with metastatic breast cancer (MBC). Proceedings of American Society for Clinical Oncology, abstract In Press, 2004.

125. Borko D. Jovanovic, Irene B. Helenowski, Alfred W. Rademaker, Raymond C. Bergan, Five methods for standardizing gene arrays and associated error rates in ratio based gene screening, American Statistical Association, 2004

126. Borko D. Jovanovic, Shan Chen, David Kelly, Irene B. Helenowski, Dhugal F. Bedford, and Raymond C. Bergan. An analysis of patterns of gene expression in treatment of cell lines with genistein. Proceedings International Conference on Mathematics, Statistics and Related Fields, 2005.

127. Yongzeng Ding, Li Xu, Borko Jovanovic, Shan Chen, David L. Kelly, William Catalona, Ximing Yang, Vijayalakshmi Ananthanarayanan, and Raymond Bergan. Faithful linear amplification of RNA from prostate tissue for microarray analysis. AACR 2004 Cancer Prevention meeting,

128. Borko Jovanovic, Yongzeng Ding, Li Xu, Shan Chen, Irene Helenowski, David L. Kelly, William Catalona, Ximing Yang, and Raymond Bergan, Simple statistical and graphical methods in evaluating adequacy of linear amplification of RNA from prostate tissue for microarray analysis. Inter-SPORE meeting, Jan 2005, Houston, TX, In Press

129. Li Xu and Raymond Bergan, MAPKAPK2 and HSP27 are downstream effectors of TGFβ-dependent cell invasion in human prostate cancer. NCI SPORE meeting, Washington, DC, 2005.

130. Li Xu and Raymond Bergan, Genistein blocks prostate cell invasion regulated by TGFβ-mediated activation of the MAPKAPK2-HSP27 pathway, Proceedings American Association for Cancer Research, abstract #.

131. Yongzeng Ding, Xu Li, Shan Chen, William Catalona, David L. Kelly, Borko Jovanovic, Irene B. Helenowski Ximing Yang, Michael Pins, and Raymond Bergan, Gene profiling of genistein’s effect in men with prostate cancer, Proceedings, American Association for Cancer Research, abstract #5265

54

132. Minalini Lakshman and Raymond Bergan, Anti-metastatic activity of dietary Genistein against human prostate cancer, using a unique in vivo model, Proceedings 2006 American Society for Investigative Pathology, abstract #3215

133. Clarissa Schumacher Craft and Raymond C. Bergan, Endoglin inhibits TGFβ-mediated Prostate Cancer (PCa) motility via activation of a non-canonical TGFβ Pathway, Proceedings, American Association for Cancer Research, 2006 TGFβ meeting, abstract #45

134. Mirzoeva, S., Kim, ND, Smith, KA, Huang, X., Bergan, RC, and Pelling JC. Inhibiiton of HIF-1 alpha and VEGF expression by the chemopreventive bioflavonoid apigenin is accompanied by Akt inhibition in human prostate carcinoma PC3-M cells. Abstract #3936, Annual Meeting of the American Association for Cancer Research, April 1-5, 2006.

135. Clarissa Schumacher-Craft, Yongzeng Ding, and Raymond Bergan, Loss of endoglin, a tumor suppressor, enhances the anti-metastatic potential of genistein. Proceedings, AACR Forefronts of Basic and Translational Cancer Research 2007, Abstract D4.

136. Young Kim, David Jacobs, Myron Gross, Raymond Bergan, Peter Gann, Kiang Liu, and Susan Gapstur. Association of serum carotenoid level with serum insulin-like growth factor (IGF)-1 and IGF-binding protein (IGFBP)-3 levels in black and white men. American Association for Cancer Research, Annual meeting, 2007, Abstract 4157

137. Yongzeng Ding, William J. Catalona, Borko D. Jovanovic, Michael Pins, Ximing J. Yang, David L. Kelly, Raymond C. Bergan, Therapeutic Reversion of the Metastatic Phenotype in Prostate Cancer, NCI SPORE meeting, Baltimore, MD, 2007.

138. Li Xu, Margaret Biddle, Matias Valsecchi, Xiaoke Huang, Wayne F. Anderson, Karl A. Scheidt, Raymond C. Bergan. Inhibiting human prostate cancer metastasis by targeting the p38 MAP kinase-HSP27 pathway, Congress of International Drug Discovery Science and Technology (IDDST)-2007: Advances and Challenges Toward Major Diseases, Xi’an, China, Nov 2007

139. Raymond C. Bergan. Discovering new drugs to inhibit prostate cancer metastasis. Education Session, AACR Frontiers of Cancer Prevention, Washington, DC 2008

140. Janet Pavese and Raymond C. Bergan. Validation of MEK4 as a Therapeutic Target for Inhibiting Human Prostate Cancer Metastasis. Center for Molecular Innovation and Drug Discovery Annual Symposium, 2009

141. Rebecca L. Farmer, Li Xu, Margaret M. Biddle, Antoinette E. Nibbs, Matias Valsecchi, Xiaoke Huang, Raymond C. Bergan and Karl A. Scheidt. Synthesis and Evaluation of Analogs of the PCa Metastasis Inhibitor Genistein. Medical Scientist Training Program National Meeting, 2009

142. Alexander Dew, Christie Babinski, Nancy Michel, Stefanie Miller, Marie Heffernan, Margerie Coomes and Raymond C. Bergan. Recruitment Strategies Used in NCI/DCP Phase

55

I/II Chemoprevention Trials. NIH/NCI Annual Site Coordinators Opportunity for Research Excellence (SCORE) meeting, Washington DC 2009.

143. Rebecca L. Farmer, Li Xu, Margaret M. Biddle, Antoinette E. Nibbs, Xiaoke Huang, Raymond C. Bergan and Karl A. Scheidt. Discovery of Potent and Non-Toxic Small Molecule Inhibitors of PCa Metastasis, American Chemical Society 2010 Annual meeting

144. Sankar Krishna, Li Xu, Rebecca Farmer, Xiaoke Huang, Antoinette Nibbs, Karl Scheidt, Wayne Anderson, Raymond Bergan. Structure of and ligand binding to Mitogen-activated Protein Kinase Kinase 4. American Cyrstalographic Association meeting 2010

145. Discovery of a novel durg, KBU2046, that inhibits conversion of human prostate cancer to a metastatic phenotype. Li Xu, Rebecca Farmer, Xiaoke Huang, Janet Pavese, Eric Voll, Ogden Irene, Margaret Biddle, Antoinette Nibbs, Matias Valsecchi,Karl A. Scheidt and Raymond C. Bergan. Frontiers in Cancer Prevention AACR 2010, Abstract B58.

146. Mitogen-activated protein kinase kinase 4 (MEK4) is a key regulator of prostate cancer progression. Janet Pavese, Irene Ogden, Xiaoke Huang, Li Xu, Raymond Bergan. American Association for Cancer Research 2011 Annual meeting; abstract Number: 1407. http://www.ncbi.nlm.nih.gov/pubmed/25019290

147. Genistein’s anti-invasion and anti-metastatic effects are linked to decreases in the expression of several different genes in Human prostate cancer that regulate metastatic behavior. Xiaoke Huang and Raymond Bergan. American Association for Cancer Research 2011 Annual meeting; abstract Number: 5244.

148. DETECTING CIRCULATING TUMOR CELLS IN PROSTATE CANCER PATIENTS: Novel Immunomagnetic Enrichment Method. Xiaoke Huang, Barry B. McGuire, Irene Ogden, Mark A. Sparrow, Li Xu, Daniel C. O’Brien, William J. Catalona, Raymond C. Bergan. American Urologic Association 2011 Annual Meeting, abstract # 1102849.

149. GENISTEIN INHIBITS PROSTATE CANCER METASTASIS BY PREVENTING CELL DETACHMENT Barry B. McGuire*, Xiaoke Huang, Irene Ogden, Daniel C. O'Brien, William J. Catalona, Raymond C. Bergan, Chicago, IL. American Urologic Association 2011 Annual Meeting, abstract # 1104134.

150. Harnessing the power of chemical information to probe biology and to uncover novel acting therapeutics. Li Xu, Rebecca Farmer, Xiaoke Huang, Matias Valsecchi, Eric Voll, Margaret Biddle, Janet Pavese, Antoinette Nibbs, Sean Pruell, Mike Avram, Karl A. Scheidt and Raymond C. Bergan. NCI Translational Science Meeting 2011, Poster Presenter.

151. Chemical-driven biological probing: discovery of a novel anti-metastatic drug. Discovery anti-metastatic drug. Li Xu, Rebecca Farmer, Xiaoke Huang, Matias Valsecchi, Janet Pavese, Eric Voll, Margaret Biddle, Antoinette Nibbs, Sean Pruell, Michael J Avram, Karl A. Scheidt

56

and Raymond C. Bergan. AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference, 2011, Abstract C177

152. Structure and inhibition of mitogen-activated protein kinase kinase 4 (MEK4): A prostate cancer pro-invasion protein. Sankar Narayan Krishna, Chi-Hao Luan, George Minasov, Ludmilla Shuvalova, Rebecca L. Farmer, Antoinette Nibbs, Karl A. Scheidt, Wayne F. Anderson, Raymond C. Bergan. American Association for Cancer Research 2012 Annual meeting; abstract Number: 4751.

153. The effect of heat shock protein 27 (HSP27) on prostate cancer cell adhesion, invasion and metastasis. Eric Voll, Irene Ogden, XiaoKe Huang, Raymond Bergan. American Association for Cancer Research 2012 Annual meeting; abstract Number: 5331.

154. Mitogen-activated protein kinase kinase 4 (MEK4) is a key regulator of prostate cancer progression. Janet Pavese, Irene Ogden, Xiaoke Huang, Li Xu, Raymond Bergan. American Association for Cancer Research 2011 Annual meeting; abstract Number: 1407.

155. Selective inhibition of cancer metastasis with a novel small therapeutic molecule. Xu L, Farmer R, Huang X, Pruell S, Voll E, Pavese J, Valsecchi M, Biddle M, Nibbs A, Avram M, Scheidt K, Bergan R. 2012 Annual meeting; abstract Number: 4752

156. Endoglin suppresses prostate cancer invasion through two distinct type II TGF-β receptors. Michael J. Breen, Diarmuid M. Moran, XiaoKe Huang and Raymond C. Bergan. American Association for Cancer Research 2012 Annual meeting; abstract Number: 491.

157. Spectral Markers for Chemoprevention of Colon Cancer: A Randomized Placebo-controlled Phase 2b trial. Hemant K. Roy, Vladimir Turzhitsky, Luz Rodriguez, Raymond Bergan, Asad Umar , Borko Janovic, Michael Goldberg, Laura Bianchi, Tat-Kit Tsang, Ramesh Wali, Irene B Helenowski, Gary Della Zanna, Yuliya Shklovskaya, Silvia Skripkauskas, Vadim Backman. AACR Frontiers in Cancer Prevention Research Conference, 2012, Temporary Abstract Number: 244403_2

158. Identifying and subtyping circulating tumor cells from breast, prostate, and pancreatic cancer patients based on distinct morphology. Daniel Adams1, R. Katherine Alpaugh2, Massimo Cristofanilli2, Stuart Martin3, Saranya Chumsri3, Monica Charpentier3, Raymond C. Bergan4, Irene May Ogden4, Susan Tsai5, Peixuan Zhu1, Olga V. Makarova6, Shuhong Li1, Platte T. Amstutz, III5, Cha-Mei Tang5. Association for Cancer Research 2013 Annual meeting, Abstract Tracking Number: 13-A-2138-AACR

159. A fluorescence-based thermal shift assay identifies inhibitors of mitogen activated protein kinase kinase 4. Sankar N. Krishna, Chi-Hao Luan, Rama K. Mishra, Matt Clutter, Li Xu, Karl A. Scheidt, Wayne F. Anderson, and Raymond C Bergan. (Selected best poster) Abstract, 2013 Northwestern Center for Molecular Innovation Drug Discovery Symposium.

57

160. Heat Shock Protein 27 (HSP27) Regulates Metastatic Progression of Human Prostate Cancer. Eric Voll, Irene Ogden, Janet Pavese, XiaoKe Huang, Li Xu, Borko Jovanovic and Raymond C Bergan. Abstract, 2013 Northwestern Center for Molecular Innovation Drug Discovery Symposium.

161. Identification of cell non-autonomous DNA damage responses in the tumor microenvironment that contribute to cancer therapy resistance. Ryan R. Gordon, Yu Sun, Raymond C. Bergan and Peter S. Nelson. Abstract, 2013 Northwestern Center for Molecular Innovation Drug Discovery Symposium.

162. Circulating tumor cells (CTCs) show specific resistance to DNA intercalating agents and promote epithelial to mesenchymal (EMT) transition and metastasis formation. Janet M Pavese and Raymond C Bergan. Abstract, 2013 Northwestern Center for Molecular Innovation Drug Discovery Symposium.

163. Using Protein Structure to Identify Novel Regulators of Melanoma Growth. Guy Watkins, Irene Ogden, Wayne Anderson, Andrew Binkowski, Paul Hoover, Spiro Getsios, Karl Scheidt, and Raymond C Bergan. Abstract, 2013 Northwestern Center for Molecular Innovation Drug Discovery Symposium.

164. A high-throughput screening platform for the identification of small molecule inhibitors of MAP2K4. Sankar Krishna, Chi-Hao Luan, Matt Clutter, Rama Mishra, Karl Scheidt, Wayne Anderson, and Raymond C. Bergan. Association for Cancer Research 2014 Annual meeting, Temporary Abstract Number: 4179

165. Cancer associated macrophage-like cells correlate with systemic therapy and pathological stage in numerous malignancies. Authors: Daniel Adams1, Stuart S Martin2, Saranya Chumsri2,3, Monica Charpentier2, Martin Edelman2, Rena Lapidus2, R. Katherine Alpaugh4, Massimo Cristofanilli5, Susan Tsai6, Cha-Mei Tang7, Raymond C. Bergan8 American Association for Clinical Oncology 2015 Annual meeting, Temporary Abstract Number: 150594

166. Cancer associated macrophage-like cells are prognostic indicators of overall survival in a variety of solid malignancies. Daniel L Adams, Diane K Adams, Steven H. Lin, Massimo Cristofanilli, Raymond C. Bergan, Jeffrey R Marks, Stuart S Martin, Saranya Chumsri, Thai Huu Ho, Rena G. Lapidus, Susan Tsai, Cha-Mei Tang, R. Katherine Alpaugh; American Society of Clinical Oncology, 2017 Annual meeting, Abstract Number: 190087

167. SMMART: Serial Measurements of Molecular and Architectural Responses to Therapy. Brett Johnson, Jamie Keck, Max Morris, Kiara Siex, Swapnil Parmar, Annette Kolodzie, Raymond Bergan, Joe Gray. Association for Cancer Research 2018 Annual meeting, abstract 3296.

168. Real time monitoring of solid tumor progression by circulating stromal cells in early and late stage disease. Daniel Adams, Raymond Bergan, Martin J. Edelman, Stuart S. Martin, Rena

58

Lapidus, Saranya Chumsri, Cha-Mei Tang, Steven H. Lin. Association for Cancer Research 2018 Annual meeting, abstract 1560.

169. Cancer associated macrophage-like (CAMLs) cells in blood predict progression and survival for all stages of solid tumors. Daniel Adams, Steven H. Lin, R. Katherine Alpaugh, Thai Ho, Jeffrey R. Marks, Stuart S. Martin, Susan Tsai, Saranya Chumsri, Cha-Mei Tang, Massimo Cristofanilli, Raymond Bergan. Association for Cancer Research 2018 Annual meeting, abstract 2631.

170. Implementing a Comprehensive Translational Oncology Platform: From Molecular Testing to Actionability. Zahi I Mitri, Swapnil Parmar, Brett Johnson, Annette Kolodzie, Jamie M Keck, Max Morris, Alexander Guimaraes , Brooke R Beckett, Uma Borate, Charles D Lopez, Kathleen A Kemmer, Joshi J Alumkal, Tomasz M Beer, Christopher L Corless, Gordon B Mills, Joe W Gray, Raymond Bergan. American Society of Clinical Oncology, 2018 Annual meeting,

171. A Phase I Trial of Inhaled Iloprost for the Prevention of Lung Cancer in Former Smokers. Mary Beth Tull, Robert L. Keith, MD; Brandi Bagwell, MA; Kelly A. Benante, MPH; Adrian J. Segura, MPH; Katrina M. Alber, MPH; Kiril Kalinichenko, MBA; Lifang Hou, MD, PhD; Borko Jovanovic, PhD; Raymond Bergan, MD; Eva Szabo, MD; Lisa Bengtson, RN, MSN, OCN; Seema A. Khan, MD; York E. Miller, MD. American Society of Clinical Oncology, 2018 Annual meeting,

172. Biospecimen management for the serial measurement of molecular and architectural responses to therapy. Brett E. Johnson, Swapnil Parmar, Kiara Siex, Anastasiya Olson, Jennifer Laverdure, Jamie Keck, Annette Kolodzie, Alexander R. Guimaraes, Christopher Corless, Joe Gray, Gordon Mills, Raymond Bergan. Association for Cancer Research 2019 Annual meeting, Abstract 480.

173. Leveraging multi-omics tumor boards for precision medicine in the OHSU SMMART Treatments Program. Jamie M. Keck, Swapnil Parmar, Ben Kong, Zahi Mitri, Christopher Corless, Annette Kolodzie, Allison Creason, Jeremy Goecks, Patrick Leyshock, Kiara Siex, Brett E. Johnson, Janice Patterson, Laura Heiser, Anastasiya Olson, Matt Viehdorfer, Georgia Mayfield, Jennifer Laverdure, Joe W. Gray, Gordon B. Mills, Raymond C. Bergan. Association for Cancer Research 2019 Annual meeting, Abstract 4929. Investigational New Drug Applications IND #: 064,645: A Phase II Study of Genistein in Patients with Localized Prostate Cancer. Patents 1. Inhibition of Protein Kinase Activity by Aptameric Action of Oligonucleotides (Patent #: 5,998,596). Role: inventor.

59

2. Catalytic Enantioselective Synthesis of Flavanones and Chromanones (US Patent # 7,851,640). Role: inventor. 3. Inhibition and Treatment of Prostate Cancer Metastasis (US Patent #s: 8,481,760, 8,742,141). Role: inventor. 4. Inhibition of Cancer Cell Motility (U.S. Patent #: 9,839,625, 10,231,949). Role: inventor. 5. Cell free screen for measuring effect of small molecules on client protein interactions with the HSP90B/CDC37 complex and resultant functional effects (US Patent Pending: U.S. Serial No. 62/628,243 -- VA ID No. 2017-383; A&A Ref. 30452.43USP1) 6. Inhibitors of cancer-mediated bone destruction (US Patent Pending: U.S. Serial No. 62/801,858 -- OHSU Tech ID No. 2670-1; provisional filed 2/6/2019) Public datasets created Gene expression profile of human prostate epithelial cells recovered by laser capture microdissection in control and genistein treated men with localized prostate cancer (GSE128339): https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE128339 Companies 1. Third Coast Therapeuticx (3CRx). Co-founder, co-owner, member Board of Directors and Chief Scientific Officer. The goal of 3CRx is to provide a platform for the development compounds discovered by us that are designed to inhibit human cancer metastasis.